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I. INTRODUCTION 
FORMULATION AND EVALUATOIN OF MONTELUKAST SODIUM  
CHEWABLE TABLETS BY DIRECT COMPRESSION METHOD 
1. Introduction 
 A tablet is a compressed solid unit dosage form containing medicaments 
with or without excipients. According to the Indian pharmacopoeia, pharmaceutical 
tablets are solid flat or biconvex dishes prepared by compressing a drug or a mixture 
of drugs, with or without excipients
1,2
. They vary in shape and differ greatly in size, 
shape and weight, depending on the amount of medicinal substances and the 
intended mode of administration. It is most popular dosage form and 70% of the 
total medicines are dispensed in the form of tablets. Tablets offer advantages over 
both patient and manufacturers.  
          Tablets are most popular dosage form due to their simplicity and economy of 
the manufacture, relative stability and convenience in packaging, shipping and 
storage. For the patients, ease of manufacturing convenience in administration, 
accurate dosing and stability compared to oral liquids, tamper proofness compared 
to capsules, safe compared to parentral dosage forms make it a popular and versatile 
dosage form
3
. 
1.1 Properties of tablets
4
 
 Should be elegant product having its own identity while being free of defects 
such as chips, cracks, discoloration and contamination. 
 Should have strength to withstand the rigors of shocks encountered in its 
production, packing, shipping and dispensing. 
 Should have the physical stability to maintain its physical attributes over 
time.  
 Must be able to release the medicament agent(s) in the body in a predictable 
and reproducible manner.  
 Must have suitable chemical stability over time so as not to allow alteration 
of medicinal agent(s). 
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1.2 Tablet is one of the most popular oral dosage forms due to the following   
potential advantages
5,6,7
 
 They are unit dosage form and they offer the greatest capabilities of all oral  
     dosage form for the greatest dose precision and the least content variability.
 
 Cost is lowest of all oral dosage forms. 
 Lighter and most compact.  
 Easiest and cheapest to package and transport. 
 Product identification is easy and rapid requiring no additional steps when 
employing an embossed and/or monogrammed punch face. 
 Easy to swallow with least tendency for hang-up. 
 Objectionable odor and bitter taste can be masked by coating techniques.  
 Suitable for large scale production. 
 Greatest chemical and microbial stability over all oral dosage form.   
1.3 Disadvantages compared to other dosage forms
8
 
 Difficult to swallow in case of children and unconscious patients.  
 The tablets usually have insufficient mechanical strength. Hence, careful 
handling is required. 
 The tablets may leave unpleasant taste and/or grittiness in mouth if not 
formulated properly. 
1.4 Pharmaceutical excipients used in tablets and capsules 
9,10        
 
 The pharmaceutical industry is ever thirsty to satisfy patient’s therapeutical 
needs and apart from active ingredients, excipients play a major role in formulation 
development.  
In addition to transporting the active drug to the site in the body where the 
drug is intended to exert its action, excipients play an important part in the 
manufacturing process. They may also be important for keeping the drug from being 
released too early in the assimilation process in places where it could damage tender 
tissue and create gastric irritation or stomach upset. 
Disintegrant helps the drug to disintegrate into particles small enough to 
reach the blood stream more quickly and few excipients protect the product's 
stability so it will be at maximum effectiveness at time of use. In addition, some 
excipients are used to aid the identification of a drug product. 
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Some excipients are used simply to make the product taste and look better. 
This improves patient compliance, especially in children. Although technically 
"inactive" from a therapeutic sense, pharmaceutical excipients are critical and 
essential components of a modern drug product. In many products, excipients make 
up the bulk of the total dosage form. Apart from the drug’s active ingredient, other 
essential components include diluents or fillers, binders, disintegrants, lubricants, 
coloring agents and preservatives. Diluents or fillers are inert ingredients that can 
significantly affect the chemical and physical properties of the final tablet thus 
affecting the biopharmaceutical profile. 
 One classic example of this is calcium salts, which can be utilized as fillers, 
which interfere with the absorption of tetracycline from the gastrointestinal tract. 
This example emphasizes that excipients may not always be inert, as they may be 
perceived. Usually tablets are designed so that the smallest tablet size which can be 
conveniently compressed is formed. Thus, if the dose is small more diluents are 
required and if the dose is high less diluents are required as not to increase the tablet 
size, which might make it difficult to swallow. 
  Diluents selection should be made carefully as physical-chemical changes 
might render the product unstable and might cause problems in manufacturing. 
Binders are added to tablet formulations to add cohesiveness to powders thereby 
providing the necessary bonding to form granules which under compaction form a 
compact mass as tablet. In other words, binders are essential to achieve the 
“hardness” of the tablet. 
 Binders are usually selected on basis of previous experience, particular 
product needs, literature or vendor data or the preference of individual scientists or 
manufacturing unit. The primary criterion when choosing a binder is its 
compatibility with other tablet components. It must add sufficient cohesion to the 
powders to allow for normal processing yet allow the tablet to disintegrate and the 
drug to dissolve upon ingestion, releasing the active ingredients for absorption. 
Disintegrant facilitate the breakup of a tablet after oral administration. 
 They can be added prior to granulation or during the lubrication step prior to 
compression or at both processing steps. The effectiveness of many disintegrants is 
affected by their position within the tablet. Since disintegration is the opposite 
operation to granulation (agglomeration) and the subsequent formation of strong 
Chapter I                                                                                                             Introduction 
Dept. of Pharmaceutics                                 4              J.K.K.Nattraja college of pharmacy 
 
compacts, one must carefully weigh these two phenomena when designing a tablet. 
Lubricants prevent sticking of the tablets to the tablet punches during the 
compression phase of the tablet manufacturing process. 
 When lubricants are added to a powder mass, they form a coat around 
individual particles which remains more or less intact during compression. 
Lubricants are mostly hydrophobic. The presence of lubricant coating may cause an 
increase in the disintegration time and a decrease in drug dissolution rate. The 
choice of a lubricant may depend upon the type of tablet being manufactured, 
dissolution, flow characteristics and requirements of the formulation in terms of 
hardness, friability and compatibility. 
 Glidants are the materials that have good flow properties and poor 
lubrication properties. Glidants improve the flow of powder into the tableting 
machines for compaction. They act to minimize the tendency of a granulation to 
separate or segregate due to excessive vibration. High speed tablet machine require 
smooth even flow of material to die cavities (tablet mold). The uniformity of tablet 
weights directly depends on how uniformly the die cavity is filled. In general many 
materials commonly referred to as lubricants possess only a minimal lubricating 
activity and are better glidants or anti-adherents. 
 Thus a blend of two or more materials may be necessary to obtain these 
properties. Pharmacists should be familiar with the components of pharmaceuticals 
products, beyond their active ingredients. In order to educate pharmacists on 
excipients that are routinely used in the pharmaceutical industry, we decided to 
examine the top 200 prescription, tablets and capsules products of 2003 and find out 
how many or which excipients are used in each product. 
 The selection will cover both brand and generic drugs. Out of the 200 
prescription drugs, the total numbers of inactive excipients used except for coating 
and coloring agents were only 94. Although the list is composed on the top 200 
drugs of 2003, very few blockbusters has been launched since then and still the 
excipients in all remains the same. 
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Table No: 1 Pharmaceutical excipients used in tablets and capsules 
No Excipients No. of times  used 
out of 200 
formulations 
Use 
1 Acacia 2 
Emulsifying agent, stabilizing 
agent, suspending agent, tablet 
binder, viscosity-increasing agent 
2 Alginate 
 
1 
Binder 
3 Alginic Acid 1 
Stabilizing agent, suspending 
agent,tablet binder, Tablet 
disintegrant, 
Viscosity-increasing agent 
4 
Aluminum 
Acetate 
1 Antiseptic 
5 Benzyl Alcohol 2 
Antimicrobial preservative, 
disinfectant,solvent 
6 Butyl Paraben 1 Antimicrobial preservative 
7 
Butylated 
Hydroxy 
Toluene 
1 Antioxidant 
8 Citric acid 1 Disintegrant 
9 
Calcium 
carbonate 
1 
Tablet and capsule diluents, 
therapeutic agent 
10 Candelilla wax 4 Binder 
11 
Croscarmellose 
sodium 
22 Tablet and capsule disintegrant 
12 
Confectioner 
sugar 
1 
Sugar coating adjunct, sweetening 
agent 
13 
Colloidal 
silicone dioxide 
22 
Adsorbent,anticaking 
agent,emulsionstabilizer, 
glidant,suspending agent,tablet 
disintegrant, thermal stabilizer, 
viscosity-increasing agent 
14 Cellulose 19 
Adsorbent, suspending agent, 
tablet and capsule diluents, tablet 
disintegrant, Adsorbent, glidant, 
suspending agent, tablet and 
capsule diluents, tablet 
disintegrant  
15 
Plain or 
anhydrous 
calcium 
phosphate 
3 Diluent 
16 Carnuba wax 12 
Binder 
 
17 Corn starch 17 
Binder 
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No Excipients No. of times  used 
out of 200 
formulations 
Use 
18 
Carboxymethyl
cellulose  
calcium 
3 
Stabilizing agent, suspending 
agent, tablet and capsule 
disintegrant, viscosity-increasing 
agent, water-absorbing agent 
19 
Calcium 
stearate 
5 Tablet and capsule lubricant 
20 
Calcium 
disodium 
EDTA 
1 Chelation 
21 Copolyvidone 1 
Film-former, granulating agent,  
tablet binder 
22 
Castor oil 
hydrogenated 
4 
Extended release agent, stiffening  
agent,tablet and capsule lubricant 
23 
Calcium 
hydrogen 
phosphate 
dihydrate 
1 
Diluent 
 
24 
Cetylpyridine 
chloride 
1 
Antimicrobial preservative, 
antiseptic, cationic surfactant, 
disinfectant, solubilizing agent, 
wetting agent 
25 Cysteine HCL 1 
Reducing Agent 
 
26 Crosspovidone 20 
Tablet disintegrant 
 
27 
calcium 
phosphate di or 
tri basic 
7 
Anticaking agent, buffer, nutrient, 
dietary supplement, Glidant 
  
28 
Dibasic 
Calcium 
Phosphate 
9 Diluent 
29 
Disodium 
hydrogen 
phosphate 
1 Buffering agent 
30 Dimethicone 1 
Antifoaming agent, Emollient 
 
31 
Erythrosine 
Sodium 
2 Color 
32 Ethyl Cellulose 3 
Coating agent, flavoring fixative, 
tablet binder, tablet filler, 
viscosity-increasing agent 
33 Gelatin 14 
Coating agent, film-former, 
gelling agent, suspending agent, 
tabletbinder, viscosity-increasing 
agent 
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No Excipients No. of times  used 
out of 200 
formulations 
Use 
34 
Glyceryl 
monooleate 
2 Non-ionic surfactant 
35 Glycerin 
 
3 
Antimicrobial preservative, 
Emollient, humectants, plasticizer, 
Solvent, sweetening agent, tonicity 
Agent 
36 Glycine 1 Tonicity agent 
37 
Glyceryl 
monostearate 
1 
Emollient, emulsifying agent, 
solubilizing agent, stabilizing 
agent,sustained-release ingredient 
38 
Glyceryl 
behenate 
1 
Coating agent, tablet binder, 
lubricant 
39 
Hydroxy 
propyl 
cellulose 
25 
Coating agent, emulsifying agent, 
suspending agent, thickening 
agent,viscosity-increasing agent 
40 
Hydroxyl 
propyl methyl 
cellulose 
45 
Coating agent, film-former, 
rate-controlling polymer for 
sustained release, stabilizing 
agent, suspending agent, viscosity-
increasing agent 
41 Hypromellose 7 
Coating agent, film-former, 
rate-controlling polymer for 
sustained release, stabilizing 
agent, suspending  
agent, tablet binder, viscosity-
increasing agent 
42 HPMC Pthalate 1 Coating agent 
43 
 
Iron oxides or 
ferric oxide 
15 Color 
44 
Iron oxide 
yellow 
5 
Color 
 
 
45 
Iron oxide red 
or ferric oxide 
6 
Color 
 
 
46 
Lactose 
hydrous or 
anhydrous or 
monohydrate or 
spray dried 
77 
Binding agent, diluent for dry-
powder inhalers, lyophilization 
aid, tablet binder, tablet and 
capsule diluent.(lactose nhydrous)  
Binding agent, diluent for dry-
powder inhalers,tablet binder, 
tablet and capsule diluents(lactose 
monhydrate), Binding agent, 
diluent for dry-powder inhalations, 
tablet and capsule diluents, 
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No Excipients No. of times  used 
out of 200 
formulations 
Use 
tablet and capsule filler(lactose 
spray dried) 
47 
Magnesium 
stearate 
108 Tablet and capsule lubricant 
48 
Microcrystallin
e 
cellulose 
61 
Adsorbent, suspending agent, 
tablet diluents, tablet disintegrant  
49 Mannitol 4 
Sweetening agent, diluents, 
tonicity agent, vehicle (bulking 
agent) for lyophilized preparations 
50 
Methyl 
cellulose 
3 
Coating agent, emulsifying agent, 
suspending agent, tablet and 
capsule 
 disintegrant, tablet binder, 
viscosity-increasing agent 
51 
Magnesium 
carbonate 
2 
Diluents 
 
52 Mineral oil 3 
Emollient, lubricant, oleaginous 
vehicle, solvent 
53 
Methacrylic 
acid copolymer 
5 Coating 
54 
Magnesium 
oxide 
2 Diluents 
55 Methyl paraben 5 
Antimicrobial preservative 
 
56 
Povidone or 
PVP 
36 
Disintegrant, dissolution aid, 
suspending agent, tablet binder 
57 PEG 40 
Ointment base, plasticizer, solvent, 
suppository base, tablet and 
capsule lubricant 
58 Polysorbate 80 19 Solubilizer 
59 
Propylene 
glycol 
10 
Antimicrobial preservative, 
disinfectant,humectants, 
plasticizer, 
Solvent, stabilizer for vitamins, 
water-miscible cosolvent 
60 
Polyethylene 
oxide 
3 
Mucoadhesive, tablet binder, 
thickening agent 
61 
Propylene 
paraben 
4 Antimicrobial preservative 
62 
Polaxamer 407 
or 188 or plain 
3 
Dispersing agent, emulsifying and 
coemulsifying agent, solubilizing 
agent, tablet lubricant, wetting 
agent 
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No Excipients No. of times  used 
out of 200 
formulations 
Use 
63 
Potassium 
bicarbonate 
1 Alkalizing agent, therapeutic agent 
64 
Potassium 
sorbate 
1 Antimicrobial preservative 
65 Potato starch 1 Binder 
66 
Phosphoric 
acid 
1 Acidifying agent 
67 
Polyoxy140 
stearate 
1 
Emulsifying agent, solubilizing 
agent, wetting agent 
68 
Sodium starch 
glycolate 
20 Tablet and capsule disintegrant 
69 
Starch 
pregelatinized 
21 
diluents, disintegrant,binder 
(starch pregelatinized Glidant        
( starch , potato, corn , wheat, rice)  
70 
Sodium 
crossmellose 
1 Disintegrant 
71 
Sodium lauryl 
sulfate 
13 
Anionic surfactant, detergent, 
emulsifying agent, skin penetrant, 
lubricant, wetting agent 
 
72 Starch 19 
Glidant, diluents, disintegrant 
binder.(starch , potato, corn , 
wheat, rice)  
73 Silicon dioxide 14 Same as colloidal silicon dioxide 
74 
Sodium 
benzoate 
2 
Antimicrobial preservative, 
lubricant 
75 Stearic acid 12 
Emulsifying agent, solubilizing 
agent, lubricant 
76 Sucrose 9 
Base for medicated confectionery, 
granulating agent, sugar coating 
adjunct, suspending agent, 
diluents, sweetening agent, 
viscosity-increasing agent 
77 Sorbic acid 3 Antimicrobial preservative 
78 
Sodium 
carbonate 
1 Carbonating agent 
79 
Saccharin 
sodium 
1 Sweetening agent 
80 
Sodium 
alginate 
1 
Stabilizing agent, suspending 
agent, disintegrant, binder, 
viscosity-increasing agent 
81 Silica gel 1 Adsorbant 
82 
Sorbiton 
monooleate 
1 
 
Solubilizer 
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No Excipients No. of times  used 
out of 200 
formulations 
Use 
83 
Sodium stearyl 
fumarate 
4 Tablet and capsule lubricant 
84 
Sodium 
chloride 
3 
Tablet and capsule diluents,  
tonicity agent 
85 
Sodium 
metabisulfite 
1 Antioxidant 
86 
Sodium citrate 
dihydrate 
1 
Alkalizing agent, buffering agent, 
emulsifier, sequestering agent 
87 Sodium starch 1 Binder 
88 
Sodium 
carboxy methyl 
cellulose 
1 
Disintegrant,  binder, stabilizing 
agent, suspending agent, 
viscosity-increasing agent, 
 Water-absorbing agent. 
89 Succinic acid 1 Acidity 
90 
Sodium 
propionate 
1 Antimicrobial preservative 
91 
Titanium 
dioxide 
49 
Coating agent, opacifier, pigment 
 
92 Talc 20 
Anticaking agent, glidant,  
diluents, lubricant 
93 Triacetin 6 
Humectant, plasticizer, solvent 
 
94 Triethyl citrate 3 
Plasticizer 
 
 
 In the tablet formulation, a range of excipients materials is normally required 
along with the active ingredient in order to give the tablet the desired properties. For 
example the reproducibility and dose homogeneity of the tablets are dependent on 
the properties of the powder mass. The tablet should also be sufficient strong to 
withstand handling, but should disintegrate after intake to facilitate drug release. The 
choice of excipients will affects all these properties. 
1.4.1 Filler 
 Fillers are used to make the tablets of sufficient for easy handling by the 
patient and to facilitate production. Tablets containing a very potent active substance 
would be very small without additional excipients. Good fillers will have good 
compact ability and flow properties, acceptable taste will be non-hygroscopic and 
good compact ability chemically inert. It may also be advantageous to have filler 
that fragment easily, since this counteracts the negative effects of lubricant additions 
to the formula. 
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1.4.2 Binder 
 A material with a high bonding ability can be used as a binder to increase the 
mechanical strength of the tablet. A binder is usually a ductile material prone to 
undergo plastic deformation. Typically binder is polymeric material often with 
disordered solid state structures. Of special importance is the deformability of the 
peripheral parts of the binder particles. Thereby this group of materials has the 
capacity of reducing interparticulate distance within the tablet, improving bond 
formation. If the entire bulk of the binder particle undergoes extensive plastic 
deformation during compression, the interparticulate voids will at least partly be 
filled and the tablet porosity will decrease.  This increase the contact area between 
the particles which promote the creation of interparticulate bonds subsequently 
increases the tablet strength. However, the effect of the binder depends on the both 
its own properties and those of the other compounds within the tablet. A binder is 
often added to the granulation liquid during wet granulation to improve the 
cohesiveness and compactability of the powder particles, which assists formation of 
granules. It is commonly accepted that binder added in dissolved form, during a 
granulation process is more effectives than used in dry powder form during direct 
compression. 
1.4.3 Disintegrating agent  
        A disintegrants are normally added to facilitate the rupture of bonds and 
subsequent disintegration of tablets. This increases the surface area of the drug 
exposed to the gastrointestinal fluids incomplete disintegration can result in 
incomplete absorption or a delay in the onset of action of the drug. There are several 
types of disintegrations acting with different mechanisms 
a) Promotion of the uptake of aqueous liquids by capillary forces. 
b) Swelling in contact with water 
c) Release if gases when in contact with water  
d) Destruction of the binder by enzymatic action. 
 Starch is a traditional  particles swells moderately in contact with water and 
tablets disrupts so called superdisintegrants they are now commonly used since these 
are primarily by extensive swelling they are effective in only small quantities. Cross 
linked sodium carboxymethyl cellulose which is effective in concentrations of 2-4%. 
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Larger particles of disintegrates have been found to swell to a greater extent and 
with faster rate than finer particles resulting in more effectiveness disintegration. 
1.4.3.1 Super Disintegrants
11,12,13     
          Super disintegrants were increased demands for faster dissolution 
requirements, there are now available.  The major groups of compounds which are 
used as superdisintegrants in many solid-dosage forms are as follows. 
1.4.3.1.1Microcrystalline cellulose (Avicel)   
Apart from its use in direct compression, microcrystalline cellulose is used as 
a diluent in tablets prepared by wet granulation, as filler in capsules and for the 
production of spheres. MCC tablets when exposed to increased humidity (75 %,one 
week) resulted in a softening and swelling of plain microcrystalline cellulose tablets. 
This change disappeared on removal of humid condition. 
Table No: 2 Comparative properties of various grades of Avicel 
AvicelGrade Features 
pH-101 
Most widely used for direct compression tabletting and wet 
granulation 
pH-102 Larger particle size, Compression properties similar to pH-101. 
pH-103 Reduced moisture content and ideal for moisture-sensitive materials 
pH-105 
Finest particle size and may be used in direct compression of 
coarser or granular or crystalline materials. It can be admixed with 
pH-101 to achieve specific flow and /or compression properties 
pH -200 
Larger particle size which offers increased flowability within 
minimum effect on compression characteristics. It can be used to 
reduce tablet weight variation and to improve content uniformity. 
Higher lubricant sensitivity and lower carrier capacity 
pH-301 
Higher density than its particle size equivalent, pH-01, providing 
increased flowability, greater tablet weight uniformity  
pH-302 
Density characteristics similar to pH-102, pH-302. Offers increased 
flowability, greater tablet weight uniformity and potential for 
smaller tablets. 
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1.4.4 Glidants, Anti-adherents and Lubricants 
 Glidants are added to increase the flow ability of the powder mass reduce 
interparticular friction and improve flow in the hopper shoe and die of the tablet 
machine. Anti-adherents can be added to decrease sticking of powder to the faces of 
the punches and die walls during compaction and lubricants is added to decrease 
friction between powder and die. Facilitating ejection of the tablet from the die 
however addition of lubricants can have negative effect on tablet strength, since they 
often reduces the creation of interparticular bond space. Further lubricants can also 
slow the drug dissolution process by introducing hydrophobic films around drug and 
excipients particles. These negative effects are especially pounced when long mixing 
times are required. Therefore the amount of lubricants should be kept relatively low 
and the mixing procedure kept short to avoid a homogenous distribution of lubricant 
throughout the powder mass. An alternative approaches could then be to admix 
granulated qualities of lubricant. 
1.4.5 Flavor, sweetener and colorants  
 Flavor and sweeteners are primarily used to improve or mask the taste of the 
drug with subsequent improvement in patient compliance. Coloring tablets has 
aesthetic value that can improve tablet identification especially when patients are 
taking number of different tablets at once.  
1.5 Manufacturing
 
1.5.1 Tablet manufacturing methods
14-24      
 Tablets are the unit solid dosage forms meant for oral use and are 
manufactured by using tablet compression machines. The tabletting mixture that is 
going to be compressed can be prepared by either of the three techniques- Wet 
granulation, Dry granulation or direct compression. Each of the individual technique 
mentioned above has their own advantages and disadvantages respectively.  
(a.)Methods for tablet preparation 
 1. Granulation method. 
  a. Wet granulation.  
  b. Dry granulation. 
 2. Direct compression method. 
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(b.) Steps involved in these methods 
Wet granulation Dry granulation Direct compression 
Blending Blending Blending 
Wet massing and screening 
Slugging/roller compaction 
- Drying 
 
- - Dry screening 
Blending(with lubricant) 
 
Blending 
(with lubricant) 
Blending  
(with lubricant) 
Compaction Compaction Compaction 
 
1.5.1.1 Wet granulation 
 Wet granulation is the process in which a liquid binder is added to a powder 
in a vessel equipped with any type of agitation that will produce agglomeration or 
granules these granules after drying are compressed to tablet form. 
1.5.1.2 Dry granulation 
 In this technique, there is no use of liquid. The process involves the 
formation of flugs. Then these flugs are screened or milled to produce granules. The 
granules formed are then compressed into tablet forms. 
1.5.1.3 Direct compression  
 In general direct compression method involves the direct compaction of 
tabletting mixture without the step of granulation, provided the tabletting mixture 
should have enough flow properties and should form a robust tablet. For suppose, if 
the tabletting mixture is not having good flow properties, we can either use direct 
compression vehicles (DCV) for improving the flow and compatibility of tabletting 
mixture or by subjecting the mixture for granulation process (wet or dry 
granulation).  
 The invention of direct compression had increased the production of tablets 
enormously all over the world due to its advantages over the other two techniques. 
The main focus that must be kept in direct compression technique is about the use of 
direct compression vehicle (DCV). Drugs must have good flow properties to be 
suitable for direct compression along with good compaction properties. By using 
DCVs, the flow properties of the drugs with poor flow can be improved and      
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hence can be manufactured by direct compression technique. Drugs with minute 
doses (potent drugs) as well as drugs with large doses are not suitable for direct 
compression due to segregation problems and large tablet sizes respectively. Here 
we mainly focused on the advantages and disadvantages of the direct compression 
technique, essential properties of DCVs, some of the examples of DCVs and the 
drugs that are suitable for direct compression technique. 
Advantages of Direct compression 
 Cost Effectiveness: The prime advantage of direct compression over wet 
granulation is economic since the direct compression requires fewer unit 
operations. This means less equipment, lower power consumption, less 
space, less time and less labor leading to reduced production cost of tablets. 
 Stability: Direct compression is more suitable for moisture and heat 
sensitive APIs, since it eliminates wetting and drying steps and increases the 
stability of active ingredients. Changes in Dissolution profiles are less likely 
to occur in tablets made by direct compression on storage than in those made 
from granulations. 
 Faster Dissolution: Disintegration or dissolution is the rate limiting step in 
absorption in case of tablets with poorly soluble API prepared by wet 
granulation. The tablets prepared by direct compression disintegrate into API 
particles instead of granules that directly come into contact with dissolution 
fluid and exhibits comparatively faster dissolution. 
 Less wear& tear of punches: The high compaction pressure involved in the 
production of tablets by slugging or roller compaction can be avoided by 
adopting direct compression. The chances of wear and tear of punches and 
dies are less. 
 Other advantages: As ingredients are processed for a shorter period of time, 
the chance for contamination is low. Due to fewer unit operations, the 
validation and documentation requirements are reduced and will become 
easier. Due to the absence of water in granulation, chance of microbial 
growth is minimal in case of tablets prepared by direct compression. 
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Limitations of Direct compression 
 Segregation: Direct compression is more prone to segregation due to the 
difference in density of the API and excipients. The dry state of the materials 
during mixing may induce static charges and lead to segregation. This may 
lead to the problems like weight variation and content non-uniformity. 
 Cost: Directly compressible excipients are the speciality products produced 
by spray drying, fluid bed drying, roller drying or co-crystallization. Hence, 
the products are relatively costly than the respective raw materials.  
 Low dilution potential: Most of the directly compressible materials can 
accommodate only 30-40 % of the poorly compressible active ingredients 
like acetaminophen that means the weight of the final tablet to deliver the 
500 mg of acetaminophen would be more than 1300 mg. The large tablets 
may create difficulty in swallowing. 
 Lubricant sensitivity: Lubricants have more adverse effect on the filler, 
which exhibit almost no fracture or shear on compression (e.g. starch 1500). 
The softening effects as well as the hydrophobic effect of alkaline stearates 
can be controlled by optimising the length of blending time to as little as 2-5 
min. 
 Variation in functionality: There is a lack of awareness in some situations 
that the excipients behave differently, depending upon the manufacturer so 
much so that substitution from one source to that of another is not possible. 
Hence, there is a need for greater quality control in purchasing of raw 
materials to assure batch uniformity.  
1.5.2 General formula for direct compression includes the following ingredients 
1. Binder-Filler (DC-vehicles) 
These DC vehicles (either binders or fillers) play an important role as  that of 
API in this method. In general, the terms binder and filler are always confusingly 
used in direct compression. But, the major difference between these two is their 
Dilution capacities. (Dilution capacity is the maximum proportion of the API that 
can be compacted into an acceptable compact by the binder or filler.)Binders have 
high dilution capacity as these are more compactible where fillers have less dilution 
capacity due to their less compatibility nature. But, these values vary depending 
upon the compacting ability of the API used.  In general, dilution capacity values of 
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binders and fillers are determined by using some reference materials which are 
difficult to compact. Eg: ascorbic acid. 
Based upon the solubility and disintegration properties of the Binders, these 
can be classified as- 
1. Binders  
 i. Soluble Binders: These are always non- disintegrating. Some of the examples are 
                  Sugars, Ploy hydric alcohols etc. 
ii. Insoluble Binders: These insoluble binders are again of two types- 
   a. Disintegrating (MCC, starch etc.) 
   b. Non-disintegrating (DCP) 
When we use soluble filler, there will be rapid release of API from the tablet, but the 
problem is that soluble erosion and release profile dominates the disintegration and 
release profile. (We observed faster release patterns in case of MCC tablets 
whencompared with similar formula where lactose is used instead of MCC). 
Factors influencing the selection of optimum DC- vehicle 
 Properties of Powders. (particle size, shape, density, solubility) 
 Properties of compacts. (flow, compatibility) 
 Stability factors. (temperature and moisture effects) 
 Others. (cost, availability etc.) 
2.Disintegrants 
 In general, we use less concentration of disintegrants in DC method when 
compared with the wet granulation method which are nothing but super 
disintegrants. This can be explained by following reasons-To minimize the softening 
and flow properties of the tabletting mixture. The required uniform particle size of 
API upon disintegration can be achieved only if the  disintegrant used is uniformly 
distributed in the tablet, which may be difficult when high loadings of API are used. 
Also when we use soluble fillers, erosion followed by dissolution occurs instead of 
disintegration, which can be avoided if we use more concentration of disintegrant or 
super disintegrants. Some of the examples of super disintegrants are sodium starch 
glycollate, crosspovidone, crosscarmellose etc. Though starch is not a super 
disintegrant, we use it in DC because it can also be used as DC filler. 
 
 
Chapter I                                                                                                             Introduction 
Dept. of Pharmaceutics                                 18              J.K.K.Nattraja college of pharmacy 
 
3. Lubricants 
  We prefer hydrophilic lubricants over the hydrophobic ones in case of DC 
method. This is because, hydrophobic ones (magnesium stearate) may form a film 
around other ingredients used in the formula which may results in the decrease of 
tablet hardness.  
This problem can be overcome by following by –  
 Blending the tableting mixture (excluding lubricant) by high shear mixtures 
and then adding the lubricant to this main blend with low shear mixing. 
 By carefully controlling the particle size and surface area of the lubricant 
used. 
 Use of hydrophilic lubricants such as stearic acid, stearyl fumerate, 
hydrogenated vegetable oils etc. 
Some works showed that ejection force, hardness, disintegration and dissolution 
times of MCC and lactose tablets were adversely effected depending upon the 
lubricant mix time. Also the type of blender used effects the crushing strength of the 
tablets. For example, crushing strength is much decreased for large industrial mixers 
compared with small laboratory blenders when same concentration of lubricant is 
used in both cases. 
1.5.3 General requirements for Direct compression 
Vehicles 
  In order to perform direct compression without any problems, we need to 
consider certain parameters which are to be maintained in optimum range and are as 
follows 
 Compactability 
 Flow properties 
1. Compactability: In general, a good conventional tablet must have enough 
hardness to withstand various stages of stress and must disintegrate and dissolve in 
almost 60 minutes. So for the tablet to have enough hardness, it should have enough 
compaction properties.  If the API dose is low, then required compactability can be 
achieved by using DC- filler.But if the API loadings are high with poor compaction 
profile, then we must use a DC-binder to achieve a strong compact. (MCC is the best 
DC- binder but can’t be used in case of low levels of insoluble API because the drug 
may get encased in the MCC aggregates formed upon disintegration and the 
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dissolution may become slower. In this case we can use soluble filler (Lactose) with 
a superdisintegrant.) When we use more than one compactable agent (binders) then 
we can expect both additive (MCC and lactose) and antagonistic effects.(cellulose or 
starch with fast dissolving sugars like dextrose, sucrose and the result is poorer 
compactability with long disintegration times). Also, as the crystal properties of 
tabletting mixture increase, its compactability decreases. So, pure crystals are 
generally inferior in terms of compactability. So, by increasing the amorphous 
nature either by spray drying or co-crystallization we can improve the 
compactability. 
Eg: Spray drying of lactose results in small alpha monohydrate crystals that are held 
together by amorphous glass. These agglomerates are superior to  normal crystals in 
terms of flow and compactability. Also, spray drying of acid hydrolyzate of 
cellulose (MCC), agglomeration of starch and partially hydrolyzed starch, Co-
crystallization of sucrose with modifieddextrins. 
2. Flow properties: “No flow, no tablets.” It is required in each and every step of 
tablet preparation. Poor flow may result in difficulties for the compression mix to 
flow from hopper to the die cavity which may cause weight variation problems. 
Granulation step increases the flow in case of wet granulation method but in case of 
DC we must use DC grade excipients for better flow. Proper flow can be attained by 
using Glidiants at levels of 0.1-0.2%. Also if the flow exceeds the optimum range, it 
may results in segregation of tablet ingredients, this will leads to content uniformity 
problems. 
Preparation of DC-vehicles 
 As we have already discussed that DC excipients are speciality products 
prepared by modification of normal ingredients, these modification can be done in 
two ways 
 Chemical modification 
 Ethyl cellulose, Methyl cellulose, HPMC, Na-CMC, Cyclodextrins etc. 
 Physical modification 
 Dextrates or compressible sugars, sorbitol, DCP etc.  
 Spray drying 
  MCC, Emdex, Spray dried Lactose etc. 
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 Crystallization 
  Dipac etc. 
 Granulation  
 Tabletose (granulated lactose) etc.  
 Co-processing 
 Cellactose : MCC, Lactose  
 Ludipress  : Lactose, PVP, Crosspovidone  
 Starlac      : Lactose, Maize starch   
 Celocol     : MCC, Calcium phosphate  
1.6 Chewable Tablet 
25-32
   
                                
 
 Tablet  is  most  popular  among  all  dosage  forms existing today because 
of convenience of self administration,  compactness and  easy manufacturing.
25
 
Many patients express difficulty in swallowing  tablets  and  hard  gelatin  
capsules, resulting in noncompliance and ineffective therapy.
26
 
 To overcome this weakness, scientists have developed innovative drug 
delivery systems known as fast dissolving tablets
.27
.  United States Food and drug 
administration (FDA) defined fast dissolving tablet (FDT) as “a solid dosage form 
containing medicinal substance or active ingredient which disintegrate rapidly  
usually  within  a  matter  of  seconds  when placed up on the tongue”.28 Their 
characteristic advantages such as administration without water, patient compliance, 
rapid onset of action, increased bioavailability and good stability make these 
tablets popular as a dosage form of choice  in the current market.
29
 
 Montelukast sodium is a leukotriene receptor antagonist (LTRA) used in 
maintenance treatment of asthma and to relieve symptoms of seasonal allergies.  It 
is usually administered orally. Montelukast sodium is freely soluble in ethanol, 
methanol and water and practically insoluble in acetonitrile and its bioavailability 
is 63%.
30,31 
 In the present study an attempt had been made to prepare chewable tablets 
of Montelukast sodium in the oral cavity with enhanced dissolution rate and hence 
improved patient compliance. The basic approach used in the development of 
Montelukast sodium chewable tablets by using co-processed super disintegrants 
containing croscarmellose sodium was studied. The concept of formulating tablets 
(FDT) of Montelukast sodium using co-processed superdisintegrants helps to 
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increase the water uptake with shortest wetting time and thereby decrease the 
disintegration time of the tablets by simple and cost effective  direct  compression  
technique.  These systems may offer superior profile with potential mucosal 
absorption, thus increase the drug bioavailability. 
 These   systems   are   also   called   mouth   dissolving tablets, melt-in-
mouth tablets, Reprimelts, porous tablets, Oro dispersible, quick dissolving or 
rapidly disintegrating tablets. Montelukast (sodium salt) is potent, selective CysLT1 
receptor anatagonist. It is indicated for the prophylaxis and chronic treatment of 
asthma in adults and pediatric patients. The drug is commercially available in 
various forms of once- daily oral dosage formulations including oral granules.  
  In addition to the therapeutic ingredients of pharmaceutical tablets 
(commonly referred to as "actives"), materials inert and non-reactive with respect to 
the actives (commonly referred to as "excipients") are added to the tablet 
formulation to confer specific properties not related to the activity of the therapeutic 
agents. Excipients such as diluents, binders, glidants, and lubricants are added as 
processing aids to make the tableting operation more effective.  
Other excipients such as microcrystalline cellulose are also added to improve the 
compression of the tablets. Still other types of excipients added to pharmaceutical 
tablets are those which enhance or retard the rate of disintegration of the tablet in 
the patient, improve the taste of the tablet, (for example sweetening agents), or 
impart a color to the tablets. In some instances such materials will provide more 
than one of these benefits to the finished tablet. Although excipients are classified 
as inert materials, they are only inert in the sense that they are not pharmaceutical 
actives and do not provide a therapeutic effect in themselves, but they make 
delivery of the therapeutic agent in the most effective manner possible. 
 Chewable tablets, regardless their geometry, represent a particular form of 
oral dosage; they are intended to be chewed in the mouth by the patient and are not 
intended to be swallowed intact. Many chewable formulations are intended to be 
used to provide a known dosage of active to children or the people who either will 
refuse to swallow an intact tablet or may have difficulty doing so. Such tablets are 
often used to administer analgesics, antacids, antibiotics, anticonvulsants, vitamins, 
and laxatives, for example. In addition to the foregoing, chewable tablets have 
several advantages which make them the method of choice in delivering certain 
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types of therapeutic agents to an even greater population. One such advantage is that 
certain types of tablets, because of the large size of the dosage, must be unusually 
large and, therefore, difficult to swallow. In some cases the effectiveness of the 
therapeutic agent is improved by the reduction in size that occurs during mastication 
of the tablets before swallowing. Furthermore, patient compliance with the 
prescribed therapy, such as antacid treatment, is enhanced by the use of smaller, 
more convenient tablets which may be consumed when it is inconvenient to swallow 
pills, for example, in the workplace. This is particularly true when the therapy would 
otherwise involve a liquid suspension of the therapeutic agent which would be 
inconvenient to transport, for example in chewable antacid tablets. 
   Excipients when added to chewable tablets must not only be inert in respect 
of the active, preferably they provide pleasant mouthfeel and/or prevent tooth 
packing, grittiness, and the like, without imparting any unpleasant characteristics to 
the tablets as they are chewed. Microcrystalline cellulose in various forms. 
 Aggregates of coprocessed microcrystalline cellulose and guar, by which 
these aggregates may be made and their physical and organoleptic properties. The 
aggregates are disclosed as being useful as fat replacements in such food 
applications as low-fat salad dressings and frozen dessert products. In this patent a 
brief mention is made of several other possible uses for these materials including 
controlled release agents, tableting excipients, flavor carriers, or bonding, bulking, 
or encapsulating agents. Except for this mention, there is no enabling disclosure 
directed toward their use as excipients nor suggestion that they possess unique 
properties that might suit them for use in pharmaceutical tablets nor any indication 
that they might provide extraordinary properties to a particular type of 
pharmaceutical tablet, for example "chewable" tablets
32
.
 
 
1.7 Asthma
33-37
   
  Asthma is a most common chronic inflammatory disease of the airways, 
characterized by hyper responsiveness to a variety of stimuli. The role of circadian 
rhythms in the pathogenesis and treatment of asthma indicates that airway resistance 
increases progressively at night in asthmatic patients. Circadian changes are seen in 
normal lung function, which reaches a low point in the early morning hours. The 
worsening of asthma at night, commonly referred to as nocturnal asthma (NA). A 
drug delivery system administered at bedtime.  Asthma is chronic respiratory 
Chapter I                                                                                                             Introduction 
Dept. of Pharmaceutics                                 23              J.K.K.Nattraja college of pharmacy 
 
disorder that causes difficulty in breathing when the airways become inflamed and 
narrow. It is usually caused by allergies. The condition can be managed by 
medication but sometimes, severe asthma attacks can be fatal.  
Oral administration could be useful for the treatment of certain diseases, such as 
asthma, gastric ulcer, hypertension, ischemic heart disease, arthritis, etc., which 
exhibit circadian rhythms. Oral drug delivery is currently the gold standard in the 
pharmaceutical industry where it is regarded as the safest, most convenient and an 
economical method of drug delivery having the highest patient compliance.  
1.7.1 Causes 
 In most cases of asthma in children, multiple triggers or precipitants exist, 
and the patterns of reactivity may change with age. Treatment can also change 
the pattern. Certain viral infections, such as respiratory syncytial virus 
(RSV) bronchiolitis in infants, predispose the child to asthma. 
 Respiratory infections: Most commonly, these are viral infections. In some 
patients, fungi (eg,allergic bronchopulmonary aspergillosis), bacteria 
(eg, mycoplasmata, pertussis) or parasites may be responsible. Most infants 
and young children who continue to have a persistent wheeze and asthma 
have high immunoglobulin E(IgE) production and eosinophilic immune 
responses (in the airways and in circulation) at the time of the first 
viral (Upper Respiratory tract infection). They also have early IgE-mediated 
responses to local aeroallergens. 
 Allergens: In patients with asthma, 2 types of bronchoconstrictor responses 
to allergens exist. 
 Early asthmatic responses occur via IgE-induced mediator release from 
mast cells within minutes of exposure and last for 20-30 minutes. 
 Late asthmatic responses occur 4-12 hours after antigen exposure and result 
in more severe symptoms that can last for hours and contribute to the 
duration and severity of the disease. Inflammatory cell infiltration and 
inflammatory mediators play a role in the late asthmatic response. Allergens 
can be foods, household inhalants (eg, animal allergens, molds, fungi, 
cocroach allergens, dust mites), or seasonal outdoor allergens 
(eg, mold spores, pollens, grass, trees). 
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 Irritants: Tobacco smoke, cold air, chemicals, perfumes, paint odors, hair 
sprays, air pollutants, and ozone can initiate BHR by inducing inflammation. 
 Weather changes: Asthma attacks can be related to changes in atmospheric 
temperature, barometric pressure, and the quality of air (eg:humidity, 
allergen and irritant content). 
 Exercise: Exercise can trigger an early asthmatic response. Mechanisms 
underlying exercise-induced asthmatic response remain somewhat uncertain. 
Heat and water loss from the airways can increase the osmolarity of the fluid 
lining the airways and result in mediator release. Cooling of the airways 
results in congestion and dilatation of bronchial vessels. During 
the rewarming phase after exercise, the changes are magnified because the 
ambient air breathed during recovery is warm rather than cool. 
 Emotional factors: In some individuals, emotional upsets clearly aggravate 
asthma. 
 Gastroesophageal reflux(GER):The presence of acid in 
the distal esophagus, mediated via vagalor other neural reflexes, 
can significantly increase airway resistance and airway reactivity. 
 Allergic rhinitis, sinusitis, and chronic URTI: Inflammatory conditions of 
the upper airways (eg, allergic rhinitis, sinusitis, or chronic and persistent 
infections) must be treated before asthmatic symptoms can be completely 
controlled. 
 Nocturnal asthma: Multiple factors have been proposed to explain 
nocturnal asthma. Circadian variation in lung function and inflammatory 
mediator release in the circulation and airways (including parenchyma) have 
been demonstrated. Other factors, such as allergen exposure and posture-
related irritation of airways (eg, GER, sinusitis) can also play a role. In some 
patients, abnormalities in CNS control of the respiratory drive may 
be present, particularly in patients with a defective hypoxic drive and 
obstructive sleep apnea. 
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1.7.2 Signs and Symptoms  
Asthma is characterized by recurrent attacks of dyspnea, cough, and 
expectoration of tenacious mucoid sputum, and usually wheezing. Symptoms may 
be mild and may occur only in association with respiratory infection, or they may 
occur in various degrees of severity to the point of being life-threatening. 
Classic allergic (atopic) asthma usually begins in childhood and becomes 
progressively more severe throughout life, although spontaneous remissions may 
occur in adulthood. Hay fever often accompanies atopic asthma. 
 The acute attack is characterized by dyspnea usually associated with 
expiratory wheezing that may be heard without a stethoscope. Cough may be present 
but is usually not the predominant symptom. There is a small group of patients with 
asthma in whom paroxysmal cough may be the predominant symptom. When 
asthma becomes prolonged, with severe intractable wheezing, it is known as status 
asthmaticus. 
1.7.3 Essentials of Diagnosis 
 Recurrent acute attacks of dyspnea, cough, and mucoid sputum, usually 
accompanied by wheezing. 
 Prolonged expiration with generalized wheezing and musical rales. 
 Bronchial obstruction reversible by drugs. 
1.7.4 Laboratory Studies 
 The sputum is characteristically tenacious and mucoid, containing "plugs" 
and "spirals." Eosinophils are seen microscopically. The differential blood count 
may show eosinophilia. In severe, acute bronchospasm, arterial hypoxemia may be 
present as a result of disturbed perfusion/ventilation relationships, alveolar 
hypoventilation, or functional right-to-left shunts. 
1.7.4.1 X-Ray Findings 
 Chest films usually show no abnormalities. Reversible hyper expansion may 
occur in severe paroxysms, or hyper expansion may persist in long-standing cases. 
Transient, migratory pulmonary infiltrations may be present. Severe attacks are 
sometimes complicated by pneumothorax. 
1.7.4.2 Differential Diagnosis 
 Distinguish wheezing from that due to other disorders such as bronchitis, 
obstructive emphysema and congestive heart failure. 
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Picture:1 Chronic Asthamatic Bronchiole. 
1.7. 5 Treatment of the patients 
 Medications used to treat asthma are generally divided  into 2 main 
categories: relievers and controllers. Relievers are best represented by the inhaled 
short-acting β2-agonists. These quick-acting bronchodilators are used to relieve 
acute intercurrent asthma symptoms, only on demand and at the minimum required 
dose and frequency. 
 Inhaled ipratropium bromide is less effective, but is occasionally used as a 
reliever medication in patients intolerant of short-acting β2-agonists. Controllers (or 
preventers) include anti-inflammatory medications, such as inhaled (and oral) 
glucocorticosteroids, leukotriene-receptor antagonists, and anti-allergic or inhaled 
nonsteroidal agents, such as cromoglycate and nedocromil. These agents 
are generally taken regularly to control asthma and prevent exacerbations. Inhaled 
glucocorticosteroids are the most effective agents in this category. 
 The controller group also includes some bronchodilators that are taken 
regularly in addition to inhaled gluco-corticosteroids to help achieve and maintain 
asthma control. These include the long-acting inhaled β2-agonists salmeterol and 
formoterol, which are the first choice in this category, as well as theophylline and 
ipratropium. The β2-agonists and ipratropium are considered of no significant 
benefit in reducing airway inflammation. 
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 There is some evidence that theophylline may have immunomodulatory 
effects, but the clinical significance of this remains to be demonstrated. Asthma 
drugs are  preferably inhaled, because this route minimizes systemic absorption and, 
thus, improves the ratio of the therapeutic benefit to the potential side-effects. The 
patient must have repeated instruction on how to use the inhaled medication. The 
recently developed oral leukotriene-receptor antagonists have good safety and 
tolerance profiles and are taken orally, which may help certain patients comply with 
treatment. 
 Asthma medications should be used at the minimum dose and frequency 
required to maintain acceptable asthma control; they should not be used as a 
substitute for proper control of the environment. Asthma medications are considered 
to be safe over many years when used appropriately. The participants in the asthma 
consensus conference have reviewed the role of each category of medication. In the 
following sections they describe briefly the mode of action, pharmacologic and 
clinical profile, mode of administration and potential side-effects of these drugs.The 
treatment may be divided into 2 phases: treatment of the acute attack and interim 
therapy, which is aimed at preventing further attacks. 
1.7.6 Asthma management  
 For all patients with asthma, monitoring should be performed on a continual 
basis based on the following parameters, which helps in the overall 
management of the disease. 
 Monitoring signs and symptoms of asthma: Patients should be taught to 
recognize inadequate asthma control, and providers should assess control at 
each visit. 
 Monitoring pulmonary function: Regularly perform spirometry and peak-
flow monitoring. 
 Monitoring quality of life and functional status: Inquire about missed work 
or school days, reduction in activities, sleep disturbances, or change in 
caregiver activities. 
 Monitoring history of asthma exacerbations: Determine if patients are 
monitoring themselves to detect exacerbations and if these exacerbations are 
self-treated or treated by health care providers. 
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 Monitoring pharmacotherapy: Ensure compliance with medications and 
usage of short-acting beta-agonists. 
 Monitoring patient-provider communication and patient satisfaction. 
1.7.7 Drug Category 
 Bronchodilators 
 Albuterol, Levalbuterol, Salmeterol, Ipratropium And Theophylline 
 Leukotriene Receptor Antagonists  
 Montelukast (Singulair), Zafirlukast 
 Corticosteroids  
 Fluticasone, Triamcinolone, Beclomethasone ,Prednisone, Budesonide 
 Mast Cell Stabilizers  
 Cromolyn  
 Combination Beta-Agonist/Corticosteroid  
 Salmeterol/Fluticasone 
 5-Lipoxygenase Inhibitors  
Zileuton   
1.8 General guidelines for collection stability data
38-40
       
 In general case stability are defined in three types. The conditions are given 
in the table that covered storage condition and time period of the study. Accelerated 
study was done at 40
o
C+/- 2
o
C/75% RH+/- 5%RH, to know the results of the study 
in short duration of time. The results of accelerated stability were then extrapolated 
to know the\e stability at ordinary conditions. Long term study in mainly done at 
25
o
C +/- 2
o
C/60
o
C RH +/- 5% RH, and the results are collected after 12 months. 
Sometimes intermediate stability studied at 30
o
C+/- 2
o
C/60% RH+/- 5%RH, done 
and data is collected after 6 months. 
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Table No: 3  ICH Guidelines 
Study Storage condition 
Minimum time period 
covered by data at 
submission 
Long term 
25
°
C +/- 2°C/60
°
C RH +/- 5% RH 
or 
30
o
C +/-2
o
C/65
o
C RH +/- 5% RH, 
12 months 
Intermediate 30
o
C +/- 2
o
C/65
o
C RH +/- 5% RH, 6 months 
Accelerated 40
o
C +/- 2
o
C/75
o
C RH +/- 5% RH, 6 months 
 
 It is up to the applicant to decide whether long term 25oC +/- 2oC/60oC RH 
+/- 5% RH or 30
o
C +/- 2
o
C/65
o
C RH +/- 5% RH is to be performed. 
 If 30oC +/- 2oC/65oC RH +/- 5% RH is long term there is no intermediate 
condition. 
1.8.1 Stability guidelines for different climatic zones 
 For convenience in planning and storage and for stability studies 
international practice identifies four climatic zones, where are described in the 
united states Europe and Japan are characterized by zones I and II. The values in are 
based on observable temperature and relatively humidity’s both in and outside in the 
rooms from which mean kinetic temperature and average humidity values are 
calculated. Derived values are based on inspections of data of individual cities and 
on allowances for a margin of safety in assignment of theses specified conditions.  
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2. LITERATURE REVIEW 
 
 Chewable tablet dosage forms continued to draw attention in the search for 
improved patient compliance and decreased incidence of adverse drug reaction.  
Many drugs exhibit bitter taste when orally administered and the bitter taste often 
causes non-compliance of patients because of the discomfort.  Therefore, 
suppression of the bitter taste has been an important subject for chewable tablets 
with simultaneous improvement in oral feeling. 
 Priyanka et al41., has formulated and evaluated montelukast sodium chewable 
tablets by wet granulation method using microcrystalline cellulose, croscarmellose 
sodium, mannitol, magnesium stearate, hydroxypropyl cellulose, ferric oxide. The 
compatability studies were carried out by mixing definite proportion of Montelukast 
sodium and microcrystalline cellulose, croscarmellose sodium, mannitol, 
magnesium stearate, hydroxypropyl cellulose, ferric oxide and cherry flavour, 
1:1,1:2.5,1:3,1:5,1:10 and kept in glass vials which has stored at 50°C (three weeks). 
Based on the optimization of parameters concluded that chewable tablet of 
Montelukast sodium can be prepared by wet granulation method using 
croscarmellose sodium as a superdisintegrants.  
 Kaur Harbir et al42., has reported pharmaceutical tablets can produced three 
methods viz. direct compression, dry granulation and wet granulation. Out of three 
methods, direct compression is most convenient and cheaper method.  
 Swati J et al43., designed and evaluated chewable tablet of levamisole (used in 
treatment of worm infestations).  As an anthelmintic, it probably works by targeting 
the nematode nicotinergic acetylcholine receptor. In the market, levamisole tablets 
are available in the form of tablets.  The chewable tablets of levamisole were 
prepared by using lactose or mannitol along with sodium starch glycolate in 
concentration ratios especially for paediatric use. Sodium saccharin and vanilla were 
used as sweetening agent and flavouring agent respectively. It was observed that the 
formulation containing lactose shows less disintegration time than formulation 
containing mannitol.
 
 Kanaka et al44., formulated and evaluated montelukast sodium chewable tablets 
by different techniques. Montelukast sodium is used for prophylaxis and chronic 
treatment of asthma. Montelukast sodium chewable tablets (5 mg) were prepared 
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and evaluated for the parameters such as average weight, hardness, tensile strength, 
friability, in vitro dissolution, and assay. The study on the dissolution profile 
revealed that product prepared from direct compression method had faster 
dissolution rate while compared to remaining batches and marketed product. Assay 
values were within the limits of 95 to 105%.
 
 Kathiresan K et al45., formulated and evaluated 5 batches of loratadine 
chewable tablets. Loratadine, H1 receptor antagonist used in the treatment of allergic 
rhinitis and urticaria.  Results showed that thickness, weight variation, friability, 
hardness, and content uniformity of all 5 formulations were within the acceptance 
limits. But in the in-vitro dissolution study, formulations 1, 2, and 5 demonstrated 
better cumulative drug release than formulations 3 and 4. However, cumulative drug 
release of formulation 5 was comparable with innovator than formulations 1 and 2. 
Hence the study concludes that loratadine chewable tablet formulated using avicel 
CE 15 and starch paste showed better characteristics of chewable tablets. 
 Hiroyuki S et al46., developed oral acetaminophen chewable tablets with 
inhibited bitter taste. Various formulations with some matrix bases and coregents’ 
were examined for development of oral chewable tablets which suppressed the bitter 
taste of acetaminophen, often used as an antipyretic for infants. Corn starch/lactose, 
cacao butter and hard fat (Witepsol H-15) were used for matrix bases, and sucrose, 
cocoa powder and commercial bitter-masking powder mixture made from lecithin 
(Benecoat BMI-40) were used for corrigents against bitter taste. For the tablets made 
of matrix base and drug, Witepsol H-15 best inhibited the bitter taste of the drug, 
and the bitter strength tended to be suppressed with increase in the Witepsol H-15 
amount. When the inhibitory effect on the bitter taste of acetaminophen solution was 
compared among the corrigents, each tended to suppress the bitter taste; especially, 
Benecoat BMI-40 exhibited a more inhibitory effect. Further, chewable tablets were 
made of one matrix base and one corrigent, and of one matrix base and two kinds of 
corrigents, their bitter taste intensities after chewing were compared. As a result, the 
tablets made of Witepsol H-15/Benecoat BMI-40/sucrose, of Witepsol H-15/cocoa 
powder/sucrose and of Witepsol H-15/sucrose best masked the bitter taste so that 
they were tolerable enough to chew and swallow. The dosage forms best masking 
bitter taste showed good release of the drug, indicating little change in 
bioavailability by masking.
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 Maddi SS et al47., designed sodium fluoride chewable tablets for dental caries. 
Chewable tablets containing low dosage fluoride content were prepared using two 
varities of celluloses and their in vitro parameters were evaluated. An eighteen 
month clinical trial revealed that both these formulations were effective in 
controlling the caries. However, ethyl cellulose is proved to be superior to 
methylcellulose as a controlled release matrix material in controlling caries. Thus 
this study recommends ethyl cellulose matrix tablets containing low fluoride content 
is an efficacious and cost effective drug device in controlling dental caries.     
 Shajan et al48., studied Montelukast sodium and Doxofylline bilayer  tablet  by 
using disintegrant such as HPMC, Crosscarmellose sodium. The sustained release 
layer of doxofylline HCl was developed by wet  granulation technique using 
polymers HPMC K100M and eudragit RL100 and the immediate release layer of 
montelukast sodium by direct compression method using superdisintegrant 
crosscarmellose sodium. The tablets were evaluated for their physical parameters. 
All the values were found to be within acceptable limits. The in vitro release was 
carried out using USP Type II apparatus. The optimized  batch was subjected to 
stability studies for 6 months at 40˚C ± 2 ˚C/ 75  % RH ± 5 % RH. The results 
suggested that the developed bilayer tablets can be used as an alternative to the 
conventional dosage form   
 Ganji Amarnath Reddy et al49., studied oral   fast   disintegrating   tablet of   
Amlodipine   Besylateusing   different   combination   of superdisintegrants like 
Croscarmellose sodium (Ac-Di-Sol), Sodium Starch Glycolate (Primogel), Cross 
Povidone (Polyplasdone) and got better bioavailability within a short duration of 
time with different formulations. For the masking of bitter taste we used 
aspartame as sweetening agent. In this study instead of drug we prepared drug 
solid dispersion so that drug’s solubility was enhanced.  
 Errolla Mahesh et al50., has prepared and studied fast dissolving tablets of 
Montelukast sodium by using novel co-processed superdisintegrants consisting of 
crospovidone and sodium starch glycolate in the different ratios (1:1,1:2 & 1:3) in 
vice versa. Montelukast sodium is a drug of choice in treatment of asthma and 
allergic rhinitis. Drug compatibility with excipients was checked by FTIR studies. 
After examining the flow properties of the powder blends the results were found to 
be within prescribed limits and indicated good flowing property and it was subjected 
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to tablet compression. All the formulations were subjected to post compression 
parameters like hardness and friability (≤1%), indicated that tablets had a good 
mechanical strength and resistance. Drug content was found to be in the range of 
93.51 to 98.79%. The wetting time is an important criteria for understanding the 
capacity of disintegrants to swell in presence of little amount of water were found to 
be in the range of 20 to 55 sec.   
 Mahalaxmi Rathnanand et al51, has formulated and evaluated chewable Tablet 
of Metformin HCl using Stevia by different techniques. The variation in the 
dissolution rate of Metformin chewable tablets made by different techniques were in 
the following order, direct compression  non-aqueous granulation  aqueous 
granulation.  Various evaluation parameters like thickness, hardness, friability, 
weight variation and drug content of the formulations were found to be satisfactory. 
Chewable immediate release metformin tablets DSC (Differential scanning 
calorimetry) and IR (Infra-red) studies showed no interaction between drug and 
excipients in optimized formulation. The optimized tablets found to be stable under 
accelerated conditions for a period of one month.                   
 M. Rajesh et al52 has formulated and characterized Albendazole chewable 
tablets Albendazole (ABZ) is a benzimidazole derivative that has been widely used 
in the treatment of worm infestations in both humans and animals. Albendazole 
chewable tablets were prepared by wet granulation method using superdisintegrants 
such as croscarmellose sodium and sodium starch glycolate. The formulations were 
prepared and the granules were evaluated for pre-compression parameters such as 
angle of repose, bulk density, tapped density, compressibility index and Hausner’s 
ratio. The results showed that all the physical parameters were within the acceptable 
limit. The stability study for the formulations showed no significance change in 
disintegration time, drug content and percentage drug release after stored at 
40°C±2°C/75%± 5% RH for the period of 30 days. 
 Mohd Abdul Hadi et al53., has developed sustained release tablets of 
Montelukast sodium by direct compression method using various polymers. The 
drug excipient mixtures were subjected to pre-formulation studies. The tablets were 
subjected to physicochemical studies, in- vitro drug release, kinetic studies and 
stability studies. FTIR and DSC studies shown there was no interaction between 
drug and polymers. The physicochemical properties of tablets were found within the 
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limits. Montelukast sodium is a leucotriene receptor antagonist used for the 
maintenance treatment of asthma. The drug release from formulations was extended 
for a period of 12 hrs. The kinetic treatment showed that the release of drug follows 
first order models. The optimized formulations were subjected to stability studies 
and shown there were no significant changes in drug content, physicochemical 
parameters and release pattern. Results of the present study indicated the suitability 
of the above mentioned polymers in the preparation of sustained release formulation 
of Montelukast sodium. 
 Janugade et al54., was prepared oral press-coated tablet by using direct 
compression and wet granulation methods to achieve the predetermined lag time. 
This press-coated tablet containing montelukast sodium in the inner core was 
formulated with an outer barrier layer by different compositions of hydrophobic 
polymer ethylcellulose and hydrophilic polymer low-substituted 
hydroxypropylcellulose.  The  effect  of  formulation  composition  on  the  barrier  
layer  comprising  both  hydrophobic  and hydrophilic excipients on the lag time of 
drug release was investigated.  
 Halder A et al55., has prepared Loperamide Hydrochloride chewable tablets by 
wet granulation technique by using croscarmellose sodium, microcrystalling 
cellulose, lactose monohydrate, magnesium stearate and SLS..etc. It has been found 
that the prepared tablets showed good physical characteristics, drug content and 
percentage of drug release.the present work aimed to prepare Loperamide 
Hydrochloride chewable tablets in combined with simethicone and develop a new 
sensitive and specific analytical procedure by HPLC suitable for application in a 
drug quality control.the method of non-aqueous granulation and adsorption of 
simethicone to dry powder blend improved hardness and provides good physical 
appearance. 
Chapter 3                                                                                                     Aim and Objective         
 
Dept. of Pharmaceutics 35 J.K.K. Nattraja college of pharmacy 
 
3. AIM AND OBJECTIVE 
 
The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site of the body, to achieve promptly and then maintain the 
desired therapeutic drug concentration that elicits the desired pharmacological action 
and to minimize the incidence and the severity of unwanted adverse effects. 
For many decades, treatment of an acute disease or a chronic illness has been 
mostly accomplished by delivering drugs using various pharmaceutical dosage 
forms, including tablets, capsules, pills, suppositories, ointments, creams, liquids, 
aerosols, and injectables as carriers. Amongst various routes of drug delivery, oral 
route is perhaps the most preferred to the patients.
 
The oral route of drug 
administration is the most important method of administering drugs for systemic 
effects. Nevertheless, it is probable that at least 90% of all drugs used to produce 
systemic effects are administered by oral route. It is very popular and successfully 
used for delivery of drugs because of convenience and ease of administration, 
greater flexibility in dosage form design, and ease of production and low cost of 
such a system.  
Chewable tablets are intend to be chewed in the mouth prior to swallowing 
and are not intended to be swallowed intact. The purpose of chewable tablet is to 
provide a unit dosage form of medication which can be easily administered to 
children or to the elderly, who may have problem in swallowing a tablet intact. It is 
also recommended to achieve rapid onset of action.  Chewable tablets are preferred 
for the drugs having high dose, the tablets of which cannot be swallowed. 
  Conversely, many patients are not able to tolerate the taste of many drugs 
when formulated as liquid dosage forms, thus leading to poor patient compliance in 
those cases. Lately recent developments in dosage form technology are 
concentrating on presenting the patient with variable dosage alternatives which 
provide good palatability and ease of administration at same time. This is especially 
valid when the preparation is to be administered to an infant or to an elderly patient. 
 Hence it was decided to formulate Montelukast chewable tablets to improve 
the compliance in children and elderly patients. Additionally, chewable tablet 
facilitate more rapid release and hence more rapid absorption of active ingredients 
and provide quick onset of action. 
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Montelukast sodium is a Leucotriene receptor antagonist used for the 
treatment of asthma. Montelukast blocks the action of Leucotriene D4 on the 
cysteinyl Leucotriene receptor in the lungs and bronchial tubes by binding to it. Its 
biological half life 2.7 to 5.5 hrs. 
The main objective of the present study was to formulate and evaluate 
Montelukast chewable tablets dosage form at the dose of 5 mg and to study the 
various formulation variables that affect the drug release by using the following 
exicipients like Mannitol, Microcrystalline cellulose, Croscarmellose sodium, 
Aspartame, Magnesium stearate, Cherry black, Euroxide and Red iron oxide . 
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4.   PLAN OF WORK  
Preformulation studies 
 Design and development of chewable tablet by direct compression method 
using superdsintigrants in different concentration. Prepared Chewable tablets of 
Montelukast sodium will be subjected for the following evaluation parameters.  
I. Pre-compression parameters 
                1.  Angle of repose 
                2.  Bulk density 
                3.  Tapped density 
                4.  Carr’s index 
                5.  Hausner ratio  
                6.  Compatibility study 
II.             Post-compression parameters 
                 1.  Appearence 
                 2.  Thickness 
                 3.  Hardness test 
                 4.  Friability test  
                 5.  Weight variation test 
       6.  In-vitro dissolution studies 
                 7.  Stability studies  
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5. DRUG AND EXCIPIENTS PROFILE 
  
1. Montelukast sodium56-60                
 Montelukast is a Leucotriene Receptor Antagonist (LTRA) used for the 
maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is 
usually administered orally. 
 Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene 
receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the 
bronchial constriction  caused by the leucotriene  and results in less inflammation. 
Because of its method of operation, it is not useful for the treatment of acute asthma 
attacks. Again because of its very specific locus of operation, it does not interact 
with other allergy medications such as theophylline. 
 Structure                                                                                                                                                                                                                                                 
NCl
H
S
-NaO
O
H
 
    
IUPAC Name: 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-
[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropane]acetate.   
 
Physical and chemical properties 
Description                  : Hygroscopic, white to off-white powder  
Empirical formula      : C35H36ClNO3S    
Molecular weight        :   586.18324 g/mol (608.17 sodium salts)  
Category                      : Antihistaminic 
Chemical nature         : Montulukast sodium is an sulfanylmethyl] 
 cyclopropyl]acetic acid  
Solubility                     : Freely soluble in ethanol, methanol, water. Practically 
 insoluble in acetonitrile  
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2.   Microcrystalline Cellulose (Avicel)
  
 
Structural formula 
 
 
Physical and chemical properties  
Description   :  White, odourless, tasteless, crystalline powder  
  composed of     porous   particles.  
Empirical formula  :  (C6H10O5)n,   n=220  
Molecular weight  :  36,000(approx) 
 Functional Category:  Tablet and capsule diluent, tablet disintegrant,  
    suspending and/or viscosity increasing agent.      
Solubility   :  Insoluble in water, dilute acids and most organic  
    solvents, slightly soluble in 5% w/v NaOH solution. 
Synonyms  :  Cellulose gel, Crystalline cellulose, Avicel PH101, 
102, Density  :  Apparent density - 0.28g/cm
3
 
               Tap density          - 0.43g/cm
3
 
Applications: 
Tablet binder/diluent (wet or dry granulation)   : 5 to 20% 
Tablet disintegrant                                          : 5 to 15% 
Tablet glidant      : 5 to 15% 
Antiadherent                                                       : 5 to 20% 
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3. Magnesium Stearate
 
 
    Structural Formula 
  
 
Physical and chemical properties  
Description  : It is a fine, white, precipitated or milled, impalpable 
    powder  of low bulk density, having a faint   
    characteristic odor and  taste. The powder is greasy to 
    touch and readily adheres to the skin.   
Empirical formula  :  C36H70MgO4  
Molecular weight  :  591.3 
Functional category  :  Tablet and capsule lubricant. 
Solubility  :   Practically insoluble in ethanol, ethanol (95%), ether 
    and water, slightly soluble in benzene and warm  
    ethanol (95%).  
Synonyms  :  Metallic stearic; Magnesium salt. 
Density                       :  Bulk volume        :    3.0-8.4 ml/g 
        Tapped volume     :     2.5-6.2 ml/g   
Applications  :  Tablet and capsule lubricant, glidant and antiadherent 
    in the concentration range of 0.25 to 5.0%. 
4.  Aspartame 
 
Structural Formula  
 
     N-a-L-Aspartyl-L-phenyialanine 1-methyl ester    
 Physical and chemical properties  
Description  :   Aspartame occurs as an off white, almost odorless  
    crystalline powder with an intensely  sweet taste 
Empirical Formula  :  C!4H18N2O5       
Molecular Weight   :  294.31 
Functional Category :  Sweetening agent. 
 Solubility   : Soluble in water and organic solvents 
Magnesium Stearate
CH
3
(CH
2
)
16
COO
CH
3
(CH
2
)
16
COO
Mg
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Synonyms  :  3-Amino-N-(a-carboxyphenethyI)succin   
    amicacid IV-merhyl ester, 3-amino-N-(a-  
    methoxycarbonyl phenethyl) succinamic acid  
    Aspartyl phenylamine methyl ester methyl  
    N-a-L-aspartyl-l.-henylalaninate 
Applications in Pharmaceutical Formulation or Technology 
Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including 
tablets, powder mixes, and vitamin preparations, it enhances flavour systems and 
can be used to mask some unpleasant taste.The approximate sweetening power is 
180-200 times that of sucrose.Therapeutically, aspartame has also been used in the 
treatment of sickle cell anemia. 
Table No 4: Pharmacopeia  Specifications. 
Test PhEur2005 USPNF23 
Characters                                  + - 
Identification                               + + 
Appearance of solution             + - 
Conductivity                                ≤ 30μS/cm - 
Specific optical rotation             +14.5-+16.5 +14.5-+16.5 
Related substances                     + - 
Heavy metals                             ≤ 10ppm ≤ 0.001% 
Loss on drying                            ≤ 4.5% ≤ 4.5% 
Sulfoted ash                                ≤ 0.2% ≤ 0.2% 
Im purl lies                                     + - 
Transmittance                             - + 
Limit of 5-benzyl-3,6-dioxo-      
2-piperazineacetic acid 
- ≤ 1.5% 
Organic volatile impurities - + 
Assay                                          98.0-102.0% 98.0-102.0% 
 + indicates Presents,  --  indicates Absent 
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5. Mannitol 
Structural Formula 
 
      
   D-Mannitol 
    
 
Physical and chemical properties  
Description 
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and 
is isomeric with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, 
or free-flowing granules, it has a sweet taste, approximately as sweet as glucose 
and half as sweet as sucrose, and imparts a cooling sensation in the mouth. 
Microscopically, it appears as orthorhombic needles when crystallized from 
alcohol. Mannitol shows polymorphism. 
Empirical Formula  :  C6H14O6   
Molecular Weight  : 182.17  
Functional Category  :  Diluent,diluent for lyphilizcd preparations, 
      Sweetening agent, tablet and capsule  
     diluents,  tonicity agent. 
Synonyms   :  Cordycepic acid,manna  sugar, D-mannite,  
     mannite, Mannogem, Pearlitol 
Applications in Pharmaceutical Formulation or Technology 
 Mannitol is widely used in pharmaceutical formulations and food products. 
In pharmaceutical preparations it is primarily used as a diluent (10-90% w/w) in 
tablet formulations, where it is of particular value since it is not hygroscopic and 
may thus it is used with moisture-sensitive active ingredients.    
 Mannitol may be used in direct-compression tablet applications for which 
the granular and spray-dried forms are available, or in wet granulations. 
Granulations containing mannitol have the advantage of being dried easily. 
Specific tablet applications include antacid preparations, glyceryl trinirrate 
tablets, and vitamin preparations. Mannitol is commonly used as an excipient in 
the manufacture of chewable tablet formulations because of its negative heat of 
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solution, sweetness, and 'mouth feel’. In lyophilized preparations, mannitol (20-
90% w/w) has been included as a carrier to produce a stiff, homogeneous cake that 
improves the appearance of the lyophilized plug in a vial. A pyrogen-free form is 
available specifically for this use. 
Mannitol has also been used to prevent thickening in aqueous antacid 
suspensions of aluminum hydroxide (<7% w/v). It has been suggested as a 
plasticizer in soft-gelatin capsules, as a component of sustained-release tablet 
formulations, and as a carrier in dry powder inhalers. It is also used as a diluent 
in rapidly dispersing oral dosage forms. It is used in food applications as a 
bulking agent. 
Therapeutically, mannitol administered parenterally is used as an osmotic 
diuretic, as a diagnostic agent for kidney function, as an adjunct in the treatment 
of acute renal failure, and as an agent to reduce intracranial pressure, treat cerebral 
edema, and reduce intraocular pressure. Given orally, mannitol is not absorbed 
significantly from the GI tract, but in large doses it can cause osmotic diarrhea. 
Typical properties   
Bulk Density    :  0.430g/cm
3 
for powders 
       0.7g/cm
3 
for granules 
Tapped density : 0.734g/cm
3 
for powders 
       0.8 g/cm
3 
for granules 
 
Table No 5: Pharmacopeial specification for mannitol 
Test JP 2001 Ph Eur2005 USP28 
Characters                                   - + + 
Identification                               + + + 
Appearance of solution             + + - 
Melting range 166-169 
o
C 165-170 
o
C 164-169 
o
C 
Conductivity                                - ≤ 20μS/cm - 
Specific optical rotation             +137
o
 - +145
o
 +23
o
 - +25
o
 +137
o
 - +145
o
 
Related substances                     - ≤ 0.1% - 
Heavy metals                             ≤ 5ppm - - 
Loss on drying                            ≤ 0.3 % ≤ 0.5 % ≤ 0.3 % 
Acidity + - + 
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Test JP 2001 Ph Eur2005 USP28 
Assay                                          ≥ 98.0 % 98.0-102.0% 96.0-101.5 % 
Sulfate                              ≤ 0.01% - ≤ 0.01% 
Arsenic ≤ 1.3 ppm - ≤ 1 ppm 
Lead - ≤ 0.5 ppm - 
Nickel + ≤ 1 ppm - 
Chloride ≤ 0.007 % - ≤ 0.007 % 
Reducing Sugars + ≤ 0.2% + 
Residue on ignition ≤ 0.1% - - 
Bacterial endo toxins - ≤ 4 IU/g(a) - 
Microbial contamination - ≤ 100/g - 
 
6. Croscarmellose Sodium  
Description 
 Croscarmellose sodium is a cross linked polymer of carboxymethyl 
cellulose sodium. Cross linking makes it an insoluble, hydrophilic, highly absorbent 
material, resulting in excellent swelling properties and its unique fibrous nature 
gives it excellent water wicking capabilities. Croscarmellose sodium provides 
superior drug dissolution and disintegration characteristics, thus improving 
bioavailability of formulations.  
Empirical Formula  
Percentage of sodium chloride     : 584.4VN/[(100–b)W] 
Percentage of sodium glycolate     :12.9w/[(100–b)W] 
Degree of acid carboxymethyl substitution(A)  : 1150M/(7102–412M–80C) 
Degree of sodium carboxymethyl substitution(S)  :(162+58A)C/(7102–80C). 
Functional category : Disintegrant for Capsules, Tablets and Granules 
Solubility : It is easily dispersed in water to form colloidal solutions.    
Insoluble in alcohol, in ether, and in most other organic solvents.  
NF category: Coating agent, suspending and/or viscosity-increasing agent,wet 
binder, film-forming agent, release-modifying agent, disintegrant. 
Synonyms :Croscarmellose sodium, modified, 
  croscarmellose natrium, 
  Cross-linked carboxymethylcellulose sodium   
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Applications  
 Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for Capsules, Tablets and Granules. In tablet formulations, 
Croscarmellose sodium may be used in both direct-compression and wet-granulation 
processes. When used in wet granulations the Croscarmellose sodium is best added 
in both the wet and dry stages of the process (intra- and extra granularly) so that the 
wicking and swelling ability of the disintegrant is best utilized. Concentrations of up 
to 5% w/w of Croscarmellose sodium may be used as a tablet disintegrant although 
normally 2% w/w is used in tablets prepared by direct compression and 3% w/w in 
tablets prepared by a wet-granulation process. 
Table no:6 Croscarmellose sodium phycio-chemical  properties 
Croscarmellose Sodium 
Identification 
A  Methylene blue - Blue fibrous mass 
B  1-Nepthol - Red-purple colour at interface 
C  K-Antimonate-Sodium test positive 
Ph 5.0 - 7.0 
Loss on Drying, NMT % 10 
Sodium Chloride and Sodium 
Glycollate, sum NMT %  
0.5 
Heavy Metals, NMT % 0.001 
Degree of Substitution 0.60 - 0.85 
Content of Water Soluble 
Material, % 
1.0 - 10.0 
Settling Volume, ml 10.0 - 30.0  
Organic Volatile Impurities  Meets the requirement 
 
7. Euroxide Red Iron Oxide 
 Ferric oxide red is used in oral pharmaceutical formulations to impart a 
distinctive appearance to the tablet of capsule. It is also useful in identification of 
products with different strengths and aesthetic appearance etc. 
8. Cherry Flavour 
 Cherry flavour functions as aflavour for improving the palatability of the 
chewable tablet formulation. It also acts as a taste masking agent. 
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6. MATERIALS AND METHODS 
 
6.1  Source of data     
 The Physicochemical properties of drug will be collected from the national and 
international journals, Internet facilities, Related articles, and Standard books from 
library of the college.      
6.2 Procurement of Drug and Excipients 
The following materials and instruments used in the experiment are of laboratory grade.  
Table No 7: Details of Materials used 
Sl. No. Materials Grade Supplier 
1.  Montelukast sodium  Pharma 
Shasun Drugs and Pharmaceuticals 
limited 
2.  Mannitol Pharma Roquette Freres 
3.  
Microcrystlline 
cellulose 
Pharma FMC Biopolymer 
4.  Croscarmellose sodium Pharma FMC Biopolymer  
5.  Aspartame Pharma The Nutra Sweet Company 
6.  
FLV ART Cherry 
501027APO551 
Pharma 
The Sensient PharmaChem 
Technology 
7.  
Euroxide Red Iron 
oxide (E7016) 
Pharma 
The Sensient PharmaChem 
Technology  
8.  Magnesium stearate Pharma Peter Greven Netherland 
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6.3 Instruments and Equipments used 
Table No 8: Details of equipments used 
Sl. No. Instruments Manufacturer/ Suppliers 
1.  FTIR Spectrophotometer. Shimadzu 1800 
2.  Rotary Compression machine Clit Pilot press Chamnnda 
3.  Dissolution test Apparatus Electrolab, USP TDT 06P 
4.   Disintegration Tester Electro lab 
5.  Hot air Oven Lawrence & Mayo 
6.  Friability Tester Electro lab, USP EF 2 
7.  Hardness Tester Monsanto 
8.  Bulk density Apparatus (digital) KE India 
9.  Digital pH meter Hanna instrument 
10.  Vernier calliper Pico India Ltd 
11.  Digital Analytical balance Mettle Toledo 
12.  HPLC Shimadzu 
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7. EXPERIMENTAL WORK 
 
7.1  Method of collection of data                                                                                                                             
 To develop the formulation and estimation of Montelukast Sodium in 
suitable pH solution.  
 Preformulation studies including solubility, compatibility with the 
excipients.  
 To evaluate the physical properties of powder blend of tablet batches such as 
angle of repose, bulk density, tapped density, compressibility index and 
hausner’s ratio. 
 Evaluation of Montelukast Sodium chewable tablets for the parameters such 
as description, hardness, friability, thickness, disintegration time, drug 
content, drug release and uniformity of weight.  
 In vitro release characteristics of Montelukast Sodium from the chewable 
tablets by dissolution test. 
 Short term stability studies of prepared formulations as per ICH guidelines. 
 Controlled room temperature: 25°C ± 2°C/60% RH ± 5% RH 
  Accelerated conditions: 40°C ± 2°C/75% RH ± 5% RH 
 Stress testing is conducted on a single batch of the tablets.  The 
study includes testing the effect of temperature at 50°C, 60°C, etc. 
and humidity at 75% RH or greater as the drug is heat sensitive. 
 Packing system; The stability studies will be conducted on the    
    drug substance packaged in a container. 
7.2 Physico-chemical properties of Montelukast Sodium 
7.2.1 Appearance 
The sample of Montelukast Sodium is white or almost white, odourless 
crystalline powder. 
7.2.2 Solubility 
 Montelukast sodium is freely soluble in water. The solubility in water is 
8.553 mg/mL. The aqueous solubility as a function of pH at 37°C is studies at 
various pH and the data presented in table. 
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Table No: 9 Solubility of Montelukast sodium in various media 
Medium used pH of Media Solubility 
(mg/mL) 
Solubility (mg/250 
mL) 
Water  6.80 8.553 2138.25 
0.5% SLS in water  6.00 15.114 3778.5 
0.001N HCl 6.56 Insoluble Insoluble 
0.01N HCl  2.95 Insoluble Insoluble 
0.1N HCl  1.25 Insoluble Insoluble 
pH 2.50 phosphate buffer  2.50 Insoluble Insoluble 
pH 3.00 Phosphate buffer  3.00 Insoluble Insoluble 
pH 3.50 Phosphate buffer  3.50 Insoluble Insoluble 
pH 4.00 Phosphate buffer  4.00 Insoluble Insoluble 
pH 4.50 Phosphate buffer  4.50 Insoluble Insoluble 
pH 5.00 Phosphate buffer  5.00 Insoluble Insoluble 
pH 5.50 Phosphate buffer  5.50 Insoluble Insoluble 
pH 6.00 Phosphate buffer  6.00 Insoluble Insoluble 
pH 6.50 Phosphate buffer  6.50 Insoluble Insoluble 
pH 7.00 Phosphate buffer  7.00 Insoluble Insoluble 
pH 7.50 Phosphate buffer  7.50 Insoluble Insoluble 
pH 8.00 Phosphate buffer  8.00 0.001 0.001 
SIF  6.80 Insoluble Insoluble 
SGF  1.20 Insoluble Insoluble 
pH 4.5 Acetate buffer  4.50 Insoluble Insoluble 
 
7.2.3 Water content 
 Montelukast sodium drug substance was reported to be hygroscopic and the 
water content was found to be 5.48%. 
7.2.4 Hygroscopicity Study 
 1 gm of the drug was kept in pre-weighed petridish in duplicate and was 
exposed to humidity condition of 40°C and 75% RH in order to assess the moisture 
uptake tendency. The moisture gain was calculated from the weight gained by the 
drug after periodic interval.Many compounds and salts are sensitive to the presence 
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of water vapour or moisture when compounds interact with moisture, they retain the 
water by either bulk or surface adsorption, capillary condensation, chemical reaction 
and, extreme cases a solution (deliquescence). 
Moisture is also an important factor that can affect the stability of the drugs 
and their formulations. Absorption of water molecules into a drug (or excipient) can 
obtain includes hydrolysis.The influence that moisture has on stability depends on 
how strongly it is bound, that is, it depends on whether the moisture is in a free or 
bound state. 
Table No:11  Hygroscopicity Classifications 
S.No.     Class          Type                     Remarks 
   1   Class1 Non-hygroscopic Essentially no moisture increase 
occur at RH below 90% 
   2   Class2 Slightly hygroscopic Essentially no moisture increase 
occur at RH below 80% 
   3   Class3 Moderately hygroscopic Moisture content does not 
increase more than 5% after 
storage for one week at RH 
below 60% 
   4   Class4 Hygroscopic Moisture content increase may 
occur at RH as low 40 to 50% 
 
If a compound is very hygroscopic, proper care should be taken to process it 
in such a way to minimize the effect of moisture. 
7.2.5 Identification of Montelukast sodium by IR 
Chemical interactions between the drug and excipients may change the  potency 
and therapeutic efficacy of the drug. To investigate the possibilities of chemical 
interaction between drug and excipients.  FTIR spectra of pure drug and optimized 
formulation were analyzed over the range 400-4000cm
-1
.  
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Picture:2 IR spectrum of Montelukast sodium 
 
7.3  Drug and Excipient Compatibility Studies 
54,55
 
 A drug excipient compatability study was performed to evaluate compatibility 
of Montelukast sodium drug substance with different excipients. Excipients were 
individually combined with the drug substance and exposed to solid-state stress 
conditions (heat, light, heat/high humidity).  
 The compatibility of various drug substance / excipient combinations was 
studied for all excipeints which were considered to find potential use in Montelukast 
chewable tablet formulation. The table below summarizes the compatability study 
results for the various excipients proposed to be employed in the formulation of 
Montelukast chewable tablets. 
Table No:10 Drug and Excipient Compatibility Studies 
Sample Interval/ condition Assay (%) Water content (%) 
Montelukast sodium 
Appearance  White powder 
Initial  99.52 6.46 
14 Days -40°C/75% RH  99.47 7.58 
14 Days – 60°C 99.46 7.25 
28 Days – 40°C/75% RH 99.38 8.22 
28 Days – 60°C 99.28 7.00 
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Montelukast sodium 
+ Microcrystalline 
cellulose PH 102 
 
Appearance  White powder 
Initial  99.59 6.18 
14 Days – 40°C/75%RH  99.39 7.17 
14 Days – 60°C 91.25 6.05 
28 Days – 40°C/75% RH  99.12 6.91 
28 Days – 60°C 87.10 6.32 
Montelukast Sodium 
+ Mannitol 
Appearance  White powder 
Initial  98.42 0.85 
14Days – 40°C/75%RH  99.36 1.11 
14 Days – 60°C 99.00 0.74 
28 Days – 40°C/75% RH  98.60 1.24 
28 Days – 60°C 99.24 0.92 
Montelukast Sodium 
+Croscarmellose 
sodium 
Appearance  White powder 
Initial  99.58 1.97 
14 Days – 40°C/75%RH  99.54 3.54 
14 Days – 60°C 99.35 3.47 
28 Days – 40°C/75% RH  99.49 4.64 
28 Days – 60°C 99.07 4.75 
Montelukast sodium 
+ Aspartame 
Appearance  White powder 
Initial  99.60 3.10 
14 Days – 40°C/75%RH  99.35 4.79 
14 Days – 60°C 97.98 3.69 
28 Days – 40°C/75% RH  99.25 3.60 
28 Days – 60°C 97.26 4.28 
Montelukast sodium  
+Red ferric oxide 
 
Appearance Pink colored powder 
Initial  99.59 6.17 
14 Days – 40°C/75%RH  99.51 7.28 
14 Days – 60°C 99.47 5.84 
28 Days – 40°C/75% RH  99.41 7.47 
28 Days – 60°C 99.29 5.69 
Montelukast sodium 
+Cherry Flavor 
Appearance  White powder 
Initial  99.48 5.64 
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14 Days – 40°C/75%RH  99.38 7.58 
14 Days – 60°C 98.50 6.32 
28 Days – 40°C/75% RH  99.26 6.29 
28 Days – 60°C 99.41 5.89 
Montelukast sodium 
+Magnesium stearate 
Appearance  White powder 
Initial  99.41 6.40 
14 Days – 40°C/75%RH  99.36 7.27 
14 Days – 60°C 99.15 7.59 
28 Days – 40°C/75% RH  99.24 7.74 
28 Days – 60°C 99.01 7.80 
 
All the powder characteristics were good and satisfied according to pharmacopeia. 
 A physical compatibility study was designed to determine the interaction of the 
drug with various excipients. The samples that is drug alone and homogeneous 
mixture of drug and each excipients were kept at accelerated conditions of 40
o
C in 
sealed glass vials, and 40
o
C /75% RH in open and closed glass vials (punctured to 
enable exposure to RH conditions for four weeks).These samples were then 
periodically examined against a control sample kept at 4
o
C 
25°C, 75% : Sealed vials                       
40°C, 75% RH (open)          : Punched vials 
40°C 75% RH (closed)        : Sealed vials 
60°C (close)                         : Sealed vials 
 The ratio for physical mixture of drug and the excipients was selected based 
on the probable concentration of the excipients in stable formulation. 
7.4 Pre-compression parameters for powder blend 
7.4.1 Flow Properties  
The flow properties of powder are critical for an efficient tabletting 
operation. Interparticulate interactions that influence bulking properties of the 
powder are also interaction that interferes with flow of powder. A comparison of 
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bulk density and tapped density gives a measure of relative importance of these 
interactions in a given powder. 
7.4.2 Bulk Density 
Calculated amount of the model drug was introduced in a 100ml graduated 
cylinder. Powder level was noted without compacting shows in table-19, Bulk 
density was calculated using the following equation: 
Bulk density = M/Vo 
M =Mass of the test sample 
Vo =Unsettled apparent volume 
7.4.3  Tapped Density 
Calculated amount of the model drug was introduced in a 100ml graduated 
cylinder. Mechanically the cylinder was tapped using the tapped density apparatus 
by raising the cylinder and allowing it to drop under its own weight that provides a 
fixed drop of 14+_2 mm at a normal rate of 250 drops per minute. The cylinder was 
tapped 1250 times initially and tapped volume measured. Tapped density was 
calculated using the following equation: 
            Tapped Density = (M)/Vf 
M= Mass of test sample 
             Vf = Final tapped volume 
Since the interparticulate interaction that influence the bulking properties of 
a powder causing interactions that interfere with powder flow, a comparison of the 
bulk and tapped densities indicate a measure of the relative importance of  these 
interaction in a given powder. Such a comparison is often used as an index of ability 
of the flow of property. 
 
7.4.4 Compressibility Index (Carr’s index) 
This parameter is the measure of propensity of powder to be compressed and 
reflect the relative importance of interparticulate interaction shows in table-19.  
      100(TD – BD) 
 Carr’s Index = -----------------------  
     TD 
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7.4.5  Hausner Ratio 
The Hausner ratio is a number that is used to correlate the flow ability of drug 
substance. 
    Tapped density 
Hausner ratio =     --------------------------      
      Bulk density 
Table No: 11 Flow ability of powder on the basis of Carr’s index and Hausner 
Ratio 
Carr’s Index Flow character Hausner ratio 
<10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>32 Very, very poor >1.60 
 
The powder flow properties of API were studied to evaluate compressibility 
of the drug since it is formulated as tablet. The result of various parameters of flow 
properties of the API are shown in table. 
7.4.6 Angle of Repose () 
          Angle of repose is defined as the maximum angle possible between the 
surface of a pile of the powder and horizontal plane. The frictional force in a loose 
powder or granules can be measured by angle of repose.  
tan  = h / r,     = tan-1 (h/r) 
Where,  is the angle of repose,   
h is height of pile 
r is radius of the base of pile 
Different ranges of flow ability in terms of angle of repose are given in table no. 8.  
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Table No :12 Relationship between Angle of Repose () and flow properties. 
Angle of Repose () (degrees) Flow 
<25 
25-30 
30-40 
>40 
Excellent 
Good 
Passable 
Very poor 
 
Method 
          A funnel was filled to the brim and the test sample was allowed to flow 
smoothly through the orifice under gravity. From the cone formed on a graph sheet 
was taken to measure the area of pile, thereby evaluating the flowability of the 
granules. Height of the pile was also measured.  
7.5 Optimization of diluents, disintegrant and lubricant concentration:  
 Microcrystalline cellulose is a versatile ingredient playing multiple roles in 
the formulations. Depending on the concentrations used, it can act as a diluent or 
disintegrant. It aids in flow of the blend and is also an important ingredients in direct 
compression techniques for tabletting. The optimization of microcrystalline cellulose 
for Montelukast sodium chewable tablets 5 mg was done by varying the 
concentrations of microcrystalline cellulose i.e 0 %, 5 %, 10 %,20 % and 27 %. 
 Croscarmellose sodium is used as a disintegrant in tablets and capsules 
formulations. Three different trials were taken with various concentrations of 
Croscarmellose sodium i.e. 0.5 %, 1% and 3 % in the formulation of Montelukast 
sodium chewable tablets. 
 Magnesium stearate is used as a lubricant in tablets and capsules 
formulations. Three different trials were taken with various concentrations of 
magnesium stearate i.e. 1.25 %, 1.50 % and 1.75 % in the formulation of 
Montelukast sodium chewable tablets. 
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Table No: 13 Percentage concentration of excipients used in the various formulations 
 
Name of ingredients 
% 
F1 
% 
F2 
% 
F3 
% 
F4 
% 
F5 
% 
F6 
% 
F7 
% 
F8 
% 
F9 
% 
F10 
Montelukast sodium 
1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.73 
Mannitol   
91.87 87.07 82.12 72.12 65.00 89.57 89.07 87.07 87.32 86.82 
MCC(Diluent) 
0.00 5.00 10.00 20.00 27.00 5.00 5.00 5.00 5.00 5.00 
CCS (Disintegrant) 
3.00 3.00 3.00 3.00 3.00 0.50 1.00 3.00 3.00 3.00 
Aspartame 
0.50 0.50 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 
Cheery Black 
1.00 1.00 1.00 1.00 1.00 1.00 0.50 0.50 0.50 0.50 
Euroxide iron  oxide 
0.40 0.20 0.15 0.15 0.15 0.60 0.20 0.20 0.20 0.20 
Magnesium stearate 
1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.25 1.75 
Total tablet weight 100 100 100 100 100 100 100 100 100 100 
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7.6 Formulation design   
The formula for preparation of  Montelukast sodium chewable tablets by direct compression  
 Table No: 14 Qualitative and quantitative composition  
Name of ingredients 
Quantity in mg/ tablet  and percentage 
F 1 % F 2 % F 3 % F4 % F 5 % 
Montelukast sodium 5.20 1.73 5.20 1.73 5.20 1.73 5.20 1.73 5.20 1.73 
Mannitol   275.6 91.87 261.2 87.07 246.35 82.12 216.35 72.12 195.00 65.00 
Microcrystalline cellulose  0.00 0.00 15.00 5.00 30.00 10.00 60.00 20.00 81.35 27.00 
Croscarmellose sodium  9.00 3.00 9.00 3.00 9.00 3.00 9.00 3.00 9.00 3.00 
Aspartame 1.50 0.50 1.50 0.50 1.50 0.50 1.50 0.50 1.50 0.50 
Cheery Black 3.00 1.00 3.00 1.00 3.00 1.00 3.00 1.00 3.00 1.00 
Euroxide iron  oxide 1.20 0.40 0.60 0.20 0.45 0.15 0.45 0.15 0.45 0.15 
Magnesium stearate 4.50 1.50 4.50 1.50 4.50 1.50 4.50 1.50 4.50 1.50 
Total tablet weight 300 100 300 100 300 100 300 100 300 100 
    Continued….. 
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Name of ingredients 
Quantity in mg/ tablet  and percentage 
F 6) % F 7 % F 8 % F 9 % F 10 % 
Montelukast sodium 5.20 1.73 5.2 1.73 5.2 1.73 5.20 1.73 5.20 1.73 
Mannitol 268.7 89.57 267.2 89.07 261.20 87.07 261.95 87.32 260.45 86.82 
Microcrystalline cellulose 15.00 5.00 15.0 5.00 15.00 5.00 15.00 5.00 15.00 5.00 
Croscarmellose sodium 1.50 0.50 3.00 1.00 9.00 3.00 9.00 3.00 9.00 3.00 
Aspartame 1.50 0.50 3.00 1.00 3.00 1.00 3.00 1.00 3.00 1.00 
CherryBlack 3.00 1.00 1.50 0.50 1.50 0.50 1.50 0.50 1.50 0.50 
Euroxide red iron oxide  0.60 0.60 0.60 0.20 0.60 0.20 0.60 0.20 0.60 0.20 
Magnesium stearate  4.50 1.50 4.50 1.50 4.50 1.50 3.75 1.25 5.25 1.75 
Total tablet weight 300 100 300 100 300 100 300 100 300 100 
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7.7 Direction compression process 
56 
Tablets was decided to prepared by either Direct compression method. 
Table No: 15 Composition of Core Tablet 
Materials %w/w of the 
total weight of 
the Tablets 
Mg/tablet Function 
Montelukast Sodium 1.73 5.20 API 
Mannitol 87.1 261.20 Diluent 
Microcrystalline cellulose  5.0 15.00 Diluent 
Croscarmellose sodium 3.0 9.00 Disintegrant 
Aspartame 1.0 3.00 Sweetening Agent 
Magnesium Stearate 1.5 4.5 Lubricant 
Cherry Black 0.5 1.5 Flavouring agent 
Euroxide Red Iron Oxide 0.2 0.6 Colorant 
Total Tablet Weight 100 300 -- 
All ingredients should be taken within the limits   
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7.8 Manufacturing process of Montelukast chewable Tablets  
Flow diagram of the manufacturing process  
  
Process 
Raw Materials 
 
Dispensing 
Deagglomeration sieve # 40ASTM  
 
s 
 
si 
Pre-blending 10 minutes 10 RPM  
 
s 
 
si 
Deagglomeration sieve # 40ASTM  
s 
 
si Blending 5 minutes at 10 RPM 
Lubrication 5 minutes at 10 RPM 
Compression 
Lubricant 
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7.9 Evaluation of Tablets 
7.9.1 Shape and colour
58
 
          Uncoated tablets were examined under a lens for the shape of the tablet and colour 
was observed by keeping the tablets in light. 
 
7.9.2 Thickness59 
          The crown thickness of individual tablet may be measured with a vernier caliper, 
which permits accurate measurements and provides information on the variation between 
tablets. Other technique employed in production control involves placing 5 or 10 tablets in 
a holding tray, where their total crown thickness may be measured with a sliding caliper 
scale. The tablet thickness was measured using vernier caliper. 
7.9.3 Hardness test 60 
          Tablets require a certain amount of strength, or hardness and resistance to friability, 
to withstand mechanical shocks of handling in manufacture, packaging and shipping. The 
hardness of the tablets was determined using Monsanto Hardness tester. It is expressed in 
Kg/cm
2
. Three tablets were randomly picked from each formulation and the mean and 
standard deviation values were calculated. 
7.9.4  Friability test
61
 
          It is the phenomenon whereby tablet surfaces are damaged and/or show evidence of 
lamination or breakage when subjected to mechanical shock or attrition. The friability of 
tablets was determined by using Roche Friabilator. It is expressed in percentage (%). Ten 
tablets were initially weighed (Winitial) and transferred into friabilator. The friabilator was 
operated at 25 rpm for 4 minutes or run up to 100 revolutions. The tablets were weighed 
again (Wfinal). The percentage friability was then calculated by, 
W(initial)--w(final) 
F =  -------------------------×100 
W(initial) 
  % Friability of tablets less than 1% is considered acceptable.  
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7.9.5 Weight variation test62 
          The tablets were selected randomly from each formulation and weighed individually 
to check for weight variation. The U.S Pharmacopoeia allows a little variation in the 
weight of a tablet. The percentage deviation in weight variation is shown in table no 10. 
Table No :16  Percentage deviation in weight variation 
Average weight of a tablet Percentage deviation 
130 mg or less 
More than 130 mg and less than 324 mg 
324 mg or more 
10 
7.5 
5 
          In all the formulations the tablet weight was more than130mg and less than    324 
mg, hence 7.5% maximum difference allowed.   
7.9.6 In-vitro disintegration time  
 The process of breakdown of a tablet into smaller particles is called as 
disintegration. The in-vitro disintegration time of a tablet was determined using 
disintegration apparatus as per I.P. specifications.  
Method 
          For a drug to be absorbed from a solid dosage form after oral administration, it must 
first be in solution, and the first important step toward this condition is usually the break-
up of the tablet, a process known as disintegration. The disintegration time of chewable 
tablets was determined in accordance with the official “United status of pharmacopoeia 
Chewable tablets” stating a maximum disintegration time of 5 minutes (USP 36).  
       One tablet in each of the 6 tubes of the basket is to be placed and the apparatus 
subjected to run. The assembly should be raised and lowered between 50 cycles per 
minute. The time in seconds taken for complete disintegration of the tablet with no 
palpable mass remaining in the apparatus was measured and recorded.  
      Disintegration or more specifically dispersion times were measured in 900 ml purified 
water according to the I.P. method without using disc at room temperature (25°C ± 2°C) 
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7.9.7 In-vitro dissolution studies
63
 
          In vitro release studies were carried out using tablet USP <711> dissolution test 
apparatus. Two objectives in the development of in-vitro dissolution tests was to show 
that,  
i)     Release of the drug from the tablet is as close as possible upto 100% and  
ii)    Rate of drug release is uniform from batch to batch and is the same as the release rate 
        from those proven to be bioavailable and clinically effective.  
Summary of general in-vitro dissolution conditions employed throughout the study to 
determine the in-vitro dissolution rate for all the formulation is given in table No 14. 
 
Table No: 17  Summary of general dissolution conditions 
Sl. No. Parameter Specifications 
1. Dissolution medium 
900 ml of 0.5%sodium 
dodecyl sulphate 
2. Temperature 37°C ± 5°C 
3. Rotation speed 50 rpm 
4. Volume withdrawn 
10 ml sample at 5,10,15,20 
and 30 minutes  
5. Wavelength  220 nm 
 
7.9.8  Dissolution by HPLC  
 
Mobile phase 
Solution A: Add 1.0 ml of ortho phosphoric acid (85% or 88%) in 1000 ml of water and 
mix. Filter and degas. 
Solution B: Acetonitrile  
Mix the solution A & B in the ratio 40:60 and degas. 
Dissolution medium preparation: 0.5 % sodium dodecyl sulphate  
Chromatographic condition 
Flow rate : 1.5 ml/minute 
Injection volume: 50µl 
Run time : 6 minutes 
Wavelength : 220 nm 
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Standard and sample preparation 
 28.6 mg of Montelukast sodium which is equivalent to 27.5 mg of Montelukast, 
transfer to 50 ml volumetric flask. Add 30 ml of methanol sonicate for 3 minutes to 
dissolve. Dilute the volume with methanol and mix. Further dilute 5 ml to 50 ml with 
dissolution medium and mix. Further dilute 5 ml to  50 ml with dissolution medium. 
Calculation:  
     A Spl         Std. wt      Spl dilution    % purity  100   585.18 
% Dissolved = ---------   x -------------- x   ----------------  x --------------x -------- x --------------- 
   A Std        Std. dilution   Spl. weight        100  LC   608.18 
 
7.9.9 Assay 
Standard preparation 
 Weighed 52 mg of Montelukast sodium standard which is equivalent to 50 mg of 
Montelukast and transfer into a 100ml volumetric flask. Add about 70 ml of mobile phase 
and sonicate for 5 minutes to dissolve and make up with mobile phase. Dilute 10 ml of 
stock solution to 50ml and mix. 
Sample preparation 
 Weighed 10 tablets, transfer into 200 ml volumetric flask and add 150 ml 
methanol, shake it for 2 mins  and mechanically shake for about 20 minutes. Further 
sonicate for 10 minutes with intermittent shaking and make up with mobile phase. Further 
dilute 10 ml to 50 ml.  
Calculation  
     A Spl         Std. wt      Spl dilution    % purity  100   585.18 
% Dissolved = ---------   x -------------- x   ----------------  x --------------x -------- x --------------- 
   A Std        Std. dilution    No. of tabs        100  LC   608.18 
7.10 Stability Studies  
          Stability of a drug has been defined as the ability of a particular formulation, in a 
specific container, to remain within its physical, chemical, therapeutic and toxicological 
specifications. 
          The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of 
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environmental factors such as temperature, humidity and light and enables recommended 
storage conditions, re-test periods and shelf lives to be established.  
          In the present study, the Montelukast Sodium Chewable Tablets are packed in 
suitable packaging and stored under the following conditions for a period as prescribed by 
ICH guidelines for accelerated studies. 
(1) 25 ± 2°C/60±5%RH 
(2) 40 ± 2°C/75±5% 
The tablets were withdrawn after period of 1, 2 and 3Months and analyzed for physical 
characterization (Appearance, hardness, friability, disintegration, dissolution etc) and drug 
content.  
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8. RESULT AND DISCUSSION 
 
8.1 Solubility of Montelukast Sodium 
 Highest dose (5.2 mg of Montelukast sodium equivalent to 5 mg of 
Montelukast) is insoluble over the entire pH range except in water and water 
containing 0.5% SLS. The highest dose of 5.2 mg of Montelukast Sodium  is soluble 
in 5200 ml which is more than 250 ml. Montelukast sodium is considered as a low 
soluble drug.  
 The solubility determination at various time intervals was not feasible as the 
drug is insoluble in other pH except water and water containing 0.5 % SLS.  
Table: 18  Solubility of Montelukast sodium in various media at different time 
interval 
 
Medium used pH of 
Media 
 
Solubility 
(mg/ml) 
(Initial) 
Solubility 
(mg/ml) 
(12
th
 hour) 
Solubility 
(mg/ml) 
(24
th
 hour) 
Water 6.80 8.553 7.361 6.510 
0.5% SLS in Water 6.00 15.114 15.083 15.000 
 
8.2 Evaluation of Precompression Parameters 
 Table: 18 Powder characterization of formulations (F1- F10) 
 Formulation 
code 
Bulk density 
(gm/ml) 
(± SD)  
Tapped 
density 
(gm/ml) 
(± SD)   
Carr’s index 
(%) 
(± SD)  
Hausner’
s ratio 
(± SD) 
  
Angle of 
repose 
(± SD)  
F1 0.526±0.094 0.666±0.120 21.02±0.03 1.26 29.56±0.04 
F2 0.555±0.089 0.666±0.91 16.6±0.074 1.20 26.21±0.079 
F3 0.588±0.074 0.714±0.069 17.64±0.065 1.21 27.89±0.051 
F4 0.526±0.101 0.666±0.034 21.02±0.094 1.26 29.19±0.067 
F5 0.476±0.093 0.588±0.113 19.04±0.093 1.23 27.97±0.084 
F6 0.526±0.099 0.666±0.074 21.02±0.099 1.26 25.86±0.044 
F7 0.50±0.107 0.558±0.07 14.9±0.107 1.17 25.52±0.021 
F8 0.476±0.112 0.555±0.108 14.23±0.034 1.16 27.61±0.099 
F9 0.50±0.094 0.625±0.043 20.0±0.0102 1.25 24.12±0.042 
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 Formulation 
code 
Bulk density 
(gm/ml) 
(± SD)  
Tapped 
density 
(gm/ml) 
(± SD)   
Carr’s index 
(%) 
(± SD)  
Hausner’
s ratio 
(± SD) 
  
Angle of 
repose 
(± SD)  
F10 0.501±0.086 0.625±0.09 20.03±0.065 1.25 25.86±0.042 
Mean±SD,(n=3) 
For the all powder blend of the all formulated batches, the angle of repose 
was found to be in the range of, thus indicating that the flow properties were fair. 
Hausner’s ratio was less than1.26 for the all batches indicating good flow properties. 
 
8.3 Evaluation of Tablets                   
Table: 19 Physical Evaluation of Montelukast Chewable Tablets 
 
Parameter 
Weight 
(mg) 
Thickness 
(mm) 
Hardness 
(kp) 
Disintegration 
time(mins’ and 
sec’’) 
Friability 
(%) 
F1 301-304 4.38-4.32 8-9 3’18’’-3’42’’ 0.18 
F2 299-303 4.36-4.39 8-9 43’’-50’’ 0.18 
F3 297-303 4.36-4.42 9-11 1’06’’-1’20’’ 0.08 
F4 298-303 4.30-4.34 8-9 51’’-1’05’’ 0.01 
F5 301-306 4.12-4.4 8-9 50’’-57’’ 0.14 
F6 299-301 4.31-4.35 8-9 2’05’’-2’27’’ 0.25 
F7 299-301 4.35-4.37 8-10 1’17’’-1’25’’ 0.18 
F8 299-303 4.36-4.39 8-9 43’’-50’’ 0.18 
F9 301-304 4.39-4.43 8-9 38’’-44’’ 0.13 
F10 300-303 4.38-4.39 8-9 47’’-53’’ 0.25 
Mean±SD,(n=3)
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8.4 Dissolution Profile of Marketed Tablets Vs Montelukast Chewable Tablets. 
Table: 20 Dissolution Profile of Marketed Tablets Vs Montelukast Chewable 
Tablets 
Percentage of Drug Release at various time points 
Time 5Minutes 10Minutes 15Minutes 20Minutes 30Minutes 45Minutes 
Marketed 
Drug 
63.9 88.9 95.2 97.6 98.8 99.3 
F1 62.2 93.8 95.2 95.2 95.3 95.3 
F2 94.2 97.2 98.0 98.7 99.0 99.6 
F3 94.0 94.6 95.2 95.2 95.3 95.0 
F4 90.8 93.2 94.0 95.0 95.8 96.4 
F5 90.7 93.7 94.5 94.8 95.2 95.0 
F6 94.0 94.6 95.2 95.2 95.3 95.3 
F7 98.8 99.7 99.9 99.9 100.3 100.2 
F8 99.8 100.2 100.6 100.8 101.0 100.9 
F9 94.9 97.3 97.9 97.8 97.6 98.3 
F10 98.1 98.7 98.9 99.0 99.0 99.2 
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 Comparative dissolution profile of marketed tablets Vs Montelukast Chewable 
Tablets 5 mg (F1 – F10) 
 
 
 
Dissolution: HPLC Chromatogram       
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Stability studies  
Table No: 21 Stability data of final formulation-F8 (Accelerated studies) 
Storage Condition: Accelerated (40°±2°C/75±5%RH) 
Parameters Limits 1 month 2 month 3 months 
Appearance 
Pink coloured, 
round shaped 
biconvex 
tablets 
Complies Complies Complies 
Hardness 8-9 kp 8.5 8.4 8.5 
Friability NMT 1% 0.18 0.19 0.18 
Disintegration 
time 
5 minutes 48’’ 51’’ 49’’ 
Dissolution 
Q=80% at 20 
min 
99% 95% 98% 
Assay 90% - 110% 103% 103.6% 102.8% 
 
Table No: 22 Stability data of final formulation-F8 (Controlled Room 
Temperature) 
Storage Condition: Controlled Room Temperature (25°±2°C/60±5%RH) 
Parameters Limits Initial  3 month 
Appearance 
Pink coloured, 
round shaped 
biconvex tablets 
Complies Complies 
Hardness 8-9 kp 8.3 8.4 
Friability NMT 1% 0.18 0.19 
Disintegration time 5 minutes 50’’ 51’’ 
Dissolution Q=80% at 20 min 99% 98% 
Assay 90% - 110% 102% 102.3% 
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Discussion 
 The formulations were evaluated for pre-compression, post-compression 
parameters and the values were found to be prescribed limits for all formulations. 
The angle of repose indicates passable to good flow properties for all the 
formulations. The results were presented in Table 18. 
 The compressed tablets were evaluated for various physical parameters such 
as description, weight variation, thickness, hardness, friability, disintegration time 
and in-vitro dissolution test. The results were presented in Table 19. Weight 
variation  was found in the range of 297 mg  to 306 mg, Thickness was found in the 
range of 4.12 mm to  4.42 mm, Hardness was found in the range of  8 to 11 kp for 
the all the formulations indicating good mechanical strengths. The percentage 
friability of all formulations were found in the range of 0.01% to 0.25%, and the 
value the below 1% is an indication of tablet with good mechanical resistance. The 
disintegration time of all formulations were found to be in the range of 38 seconds to 
3 minutes 42 seconds. The drug content of the all tablets was found in the range of 
95.2 % to 101 % of Montelukast sodium, which was with the acceptance criteria.The 
results were presented in  Table 20. 
  Montelukast sodium chewable tablets from all formulations and marketed 
sample was subjected to in-vitro release studies. The formulation F1- F5 were 
Prepared with MCC (0 %, 5%, 10%, 20% &27%), CCS (3%) and magnesium 
stearate (1.5%). The release of the Montelukast sodium from formulations F1- F5 
was 95.3%, 99.0%, 95.3%, 95.83% and 95.2 % respectively in 30 minutes.  
 The formulation F6- F8 was prepared with MCC (5%), CCS (0.5 %, 1 % and 
3%) and magnesium stearate (1.5%). The release of the Montelukast sodium from 
formulations F6- F8 was 95.3%, 100.3% and 101 % respectively in 30 minutes.  
 The formulation F9- F10 was prepared with MCC (5%), CCS (3%) and 
magnesium stearate (1.25 % and 1.75 %). The release of the Montelukast sodium 
from formulations F9- F10 was 97.6% and 99 % respectively in 30 minutes.  
 The drug release datas of the all formulations were compared with marketed 
sample of Montelukast sodium. The release of the Montelukast sodium from the 
Marketed sample was 98.8% at 30 minutes. From the above results of all 
formulations were well within the limit (Q=80% at 30 minutes as per USP <711>, 
2013). 
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 The formulation F8 was stored at 40°C±2°C/75 ± 5%RH, 25°C±2°C/60± 
5%RH for 3 months and evaluated for any changes in the Physical appearance, 
hardness, friability, disintegration time, in-vitro dissolution and Assay. The results 
revealed that there was no significance change in the appearance, hardness, 
friability, disintegration time, in-vitro dissolution and Assay after 3 months. The 
stability study results were presented in Table 21 and 22. 
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9. SUMMARY AND CONCLUSION 
  From the above compiled data it was concluded that pharmaceutical tablets  
Can be produced by three methods viz, direct compression, dry granulation and wet 
granulation. Out of these three methods direct compression is the most convenient 
and cheaper method. 
 Based on the optimization of the parameters concluded that chewable tablets 
of Montelukast sodium can be prepared by direct compression method using 
croscarmellose sodium as superdisintegrants. Chewable tablet of Montelukast 
sodium with 3% of croscarmellose sodium and 5% of microcrystalline cellulose 
shown better drug release of 101.0% at 30 minutes. The stability study of 
Formulation F8 revealed that the drug was stable under accelerated and  long term 
stability conditions for 3 months. Hence the Formula F8 containing Montelukast 
sodium 5 mg has been formulated as a chewable tablet by direct compression 
method, which satisfied all the criteria for chewable tablets. 
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